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Chapter 1  Introduction 
 
1-1.  Expression of genetic information and their regulation 
 
 DNA has an important role to play in holding the genetic code of the many viruses and 
all of the cells of living matters. The completion of decoding the sequence of the human 
genome composed of ”about 3 billion bases” was declared in 2003, and common interest 
is shifting to the research on the practical use of the genetic code of the human genome 
recently. Some genetic code may give us the information to cure specific disease. 
Chemical genetics also has been started aiming at developing novel medicine.  
 The genetic code is stored in the arrangement of DNA that consists of four kinds of 
nucleobases, adenine, guanine, cytosine and thymine. DNA is not directly translated into 
protein. At first, the genetic information in the DNA is transcribed into RNA. After an 
appropriate splicing, a mature RNA is translated into a polypeptide. The scheme of this 
gene expression called central dogma, is precisely regulated by various mechanisms. 
Especially, the interaction of the RNA and the protein regulates a lot of function in the cell, 
such as transcription, RNA splicing, and translation. 
 Although most intracellular DNAs fold as double helical conformation, the single strand 
RNA can have a precisely fold tertiary structure like a protein. Since the single strand 
RNA have also complementary short sequence, RNA is folded up by the base pairing 
into secondary structure like a hairpin loop, or bulge and an internal loop1 (Figure 1-1). 
These special structure parts are often used as a protein-binding site. Design and 
synthesis of the molecules that recognizes and binds to these specific parts of the RNA 
might regulate specific function in the cell.2, 3 
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Figure 1-1  The various secondary structure of RNA 
 
 The ribozyme which catalyzes, intron splicing for example, the reaction in the living 
organism in the absence of protein was discovered,4 and the expression control factor 
for the response of the metabolic substance in the cell called a riboswitch was found.5-7 
And it was reported by them that expression control of a genetic code is performed by 
these expression control factors.4-7 Although artificial gene silencing or restriction used to 
mostly depended on the antisense technology. Recent discovery, RNAi and riboswitch 
for example, have been uncovering the other roles of RNA as a gene regulator. However, 
since genetic code expression was performed through RNA from DNA in fact, in this 
study, I have determined the binding affinity the synthetic compounds with various RNAs, 
and discovery of the molecules that recognizes intricate structures of RNA specifically. 
Discovery of the small molecules which bind to specific RNA might enable to regulate 
genetic expression, also, that may develop novel gene therapy as well (Figure 1-2). 
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Figure 1-2  Expression of genetic information and their regulation 
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1-2.  Human immunodeficiency virus (HIV) and their RNA structure 
 
 HIV (human immunodeficiency virus) is the retrovirus that causes AIDS (acquired 
immunodeficiency syndrome). HIV is the envelope type of viruses. Its diameter is 110 nm, 
an artillery shell type core including reverse transcriptase and two RNA genomes made 
of about 9,500 bases8 (Figure 1-3). 
 
 
 
Figure 1-3  Structure of HIV particle 
 
 Viral DNA consists of gag (group specific antigen) gene which encodes basic core 
proteins, pol (polymerase) gene which encodes reverse transcriptase, env (envelope) 
gene which encodes coat protein, furthermore, LTR (long terminal repeat) which exists in 
the both ends of 5' and 3’ of a viral RNA, the gene cluster considered to be related to 
proliferation of the large number of virus containing Tat (trans-activator) and Rev 
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(regulatory protein of viral expression) 9, 10 (Figure 1-4). 
 
 
 
Figure 1-4  Structure of HIV particle 
 
 The proliferation mechanism of HIV is roughly classified into the adsorption and fusion 
for host cells, the reverse transcription of virus RNA, integration to the DNA of the host 
cell and production of a viral particle. At first, gp120 encoded by the env gene of the virus 
interact with both the glycoprotein molecule (CD4) which are the main virus receptors in 
a host cell membrane and chemokine receptor (CXCR4), and enters into a cell (Figure 
1-5). After entry into a host cell, reverse transcription is carried out to the DNA by its own 
reverse transcriptase, and this is integrated into the host DNA by suitable expression of 
the LTR gene region that has an important role in the process of the transcription 
initiation and the reverse transcription.9 
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Figure 1-5  Infection of HIV virus 
 
 LTR has a TAR (trans-activation response element) region with a special structure, it 
binds to the Tat protein (composition from 86 residues) specifically which is an activating 
transcription factor produced by translation of an early stage, and expression of HIV is 
promoted even hundreds times by this activating transfer.10-13 The RRE (rev responsive 
element) which is the base sequence having the higher order structure in the env region 
of virus RNA recognizes specifically and binds to the Rev (regulatory protein of virion 
expression) protein which is an activation transcription factor produced by translation of 
an early stage as well as Tat protein14-19 (Figure 1-6) (Figure 1-7). In this study, I have 
pay attention to discover the compound of which bind to TAR RNA or RRE RNA 
specifically in order to inhibit multiplication of the virus. 
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Figure 1-6  Schematic illustration of the regulatory system of transcription (HIV) 
 
 
 
Figure 1-7  TAR-Tat complex and RRE-Rev complex 
 
 As I have discussed, it is becoming clear that various mechanisms work, and are 
adjusted in order to HIV virus multiplication. On the other hand, the study about the 
treatment approach of AIDS is also advanced by a number of researchers. There are 
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representative examples of the treatment approach for AIDS. Development of the drug 
such as (1) the vaccine to kill the virus or the cell infected the virus, (2) the inhibitor which 
prevented the invasion to the virus and (3) the inhibitor of the reverse transcriptase have 
been reported. Among these, reverse transcriptase inhibitor AZT has been developed as 
the first anti-HIV drug in 1987.20 Furthermore, another reverse transcriptase inhibitor 
(ddC, ddI) have been also reported.20 Thus, it is thought that reverse transcriptase 
inhibitor is the most important method as chemotherapy to an HIV. However, it is a 
problem that these drugs have strong side effects and the appearance of the resistant 
virus. In this research, I tried to search the novel reverse transcriptase inhibitor 
specifically binding to TAR RNA or RRE RNA in order to inhibit this multiplication 
mechanism.  
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1-3.  Amino sugar derivatives as a binding molecule toward the RNA 
     “Aminoglycoside antibiotics” 
 
 As described 1-1 and 1-2, it is expect that the discovery of small molecule that 
specifically bind to a specific RNA could be the novel type of medicine. Since compounds 
with low molecular weight, such as an aminoglycoside has an excellence in the 
permeability across a cell membrane or nuclear membrane compared to ones with high 
molecular weight, such as a protein. It is expected that the compound with low molecular 
weight is effective in medical treatment that related to gene expression. 
 Although design of sequence-specific DNA-binding molecules have been established,21 
due to its intricate structure, that for RNA has not been established. However, a few 
examples for the design of the RNA-binding molecules have been reported. One of the 
strategies is employing polycyclic aromatic stacking molecule, such as ethidium or 
acridine, as a starting material. The other is employing the RNA-binding natural 
compounds, such as aminoglycoside antibiotics. Aminoglycosides have been studied not 
only as an antibacterial reagent but also as a scaffold to construct an RNA binding 
molecule.22-25 
 There are two major aims to construct an RNA-binding molecule starting from the 
aminoglycoside. One aim is how to enhance the binding affinities of the aminoglycoside 
toward RNA. The other is how to acquire the binding specificity. Due to positive charge of 
the aminoglycoside antibiotics, the driving force of the binding interaction depends on 
electrostatic interaction. That kind of interaction may abolish the binding specificity. For 
example, neomycin, kanamycin, paromomycin and their derivatives with similar chemical 
structures (Figure 1-8) can bind to the A-site of 16S rRNA in the 30S subunit of the 
bacterial ribosome, resulting in interference or blockage of protein biosynthesis in 
bacterial infections.26-33 Also, they inhibit the binding of TAR-Tat and RRE-Rev.34-38 
Furthermore, we can easily find that some of the aminoglycosides have neamine unit as 
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their consensus structure (Figure 1-8). We knew that neamine inhibits RRE-Rev and 
TAR-Tat interaction with micromolar of dissociation constant.39  
 Other than, aminoglycosides bind to several kinds of RNA fragment with micromolar 
level of dissociation constants. Nevertheless, it is thought that an appropriate 
modification to the aminoglycoside may improve not only binding affinity but also binding 
specificity of the aminoglycoside toward some specific RNA fragment.40-44 
 
 
 
Figure 1-8  Aminoglycoside antibiotics 
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1-4.  The Recent studies for the construction of RNA-binding molecules based 
on amino saccharide as a scaffold 
 
 Aminoglycoside antibiotics bind to several kinds of RNA fragments with micromolar 
level of dissociation constants. Although aminoglycosides are known as an antibacterial 
reagent, the existence of the pathogens having aminoglycoside-resistance has triggered 
the synthetic study of non-natural type of aminoglycoside derivatives.45-47 One of the 
recent focuses is directed to the discovery of potentially neamine-like small molecules 
with synthetic strategy. Due to multiple roles of RNAs, the discovery of small molecules 
that bind to the RNA specifically may provide novel RNA-targeted drugs. There are 
several reports which showed appropriate modifications48-50 (Figure 1-9) or 
dimerization51-52 (Figure 1-10) of neamine enhances its binding toward RNA. Under 
these circumstances, I have been attempted neamine as minimum skeleton that bind to 
RNA, and employed as a scaffold to construct the novel RNA-binding reagent. In 
addition, several groups also have reported the syntheses of small molecules by 
mimicking neamine using carbohydrate53 (Figure 1-11) However, most of these small 
molecules reported so far have indicated only a modestly enhanced and selectivity for 
the RNA. 
 
 
 
Figure 1-9  The designed the modified neamine 
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Figure 1-10  An example of designed neamine 
 
 
 
Figure 1-11  The designed neamine mimics 
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1-5.  Strategies of this work 
 
 In this study, I have chosen two RNAs derived from HIV-1 as the targets and designed 
the compound so that specifically bind to the RNAs in order to inhibit the binding of the 
corresponding viral proteins.  
 As described in 1-3 and 1-4, a number of research groups have been attempted to 
employ neamine as a minimum skeleton that binds to RNA and as a scaffold to construct 
an RNA-binding reagent. However, most of the small molecules reported so far have 
indicated only a modest affinity and selectivity for the target RNA. Then I have designed 
non-reducing amino disaccharides (trehalosamine) and aromatic group-modified amino 
saccharide (aromatic aminoglycoside) as novel neamine mimics (Figure 1-12 Study 1), 
and nucleobase modified neamines with a lysine as a linker (NbKε-neamine) as novel 
modified neamines (Figure 1-12 Study 2). 
 The compounds that have the structure of non-reducing disaccharides have a number 
of excellent functions and they have played the important role in the life. In this study, I 
have attempt to the non-reducing disaccharide as a candidate of a novel scaffold that 
displaces neamine. 
 Aromatic aminoglycoside has an aromatic aglycone structure which replaces the 
2-deoxystreptamine unit of neamine with 2,4-diaminophenol, and the aromatic group is 
expected to increase the RNA-binding affinities by π-π stacking effects. 
 Most of aminoglycosides which is capable of binds to the A-site of 16S rRNA with 
modest binding affinity have 6’-amino group.54 However modified neamine at 6’-amino 
group bound to either TAR or RRE RNA.55-57 Therefore, I have decided to focuse on the 
modification at the 6’-amino group of neamine. When the nucleobase was introduced at 
α-amino group of lysine or an arginine as a linker the binding affinity was not depend on 
the nucleobase but depend on the amino acid as a linker.1 An appropriate distance 
between the nucleobase and the neamine might clarify the binding specificity derived 
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from the difference of nucelobase. 
 I have chosen TAR and RRE RNA as the targets and designed trehalosamine aromatic 
aminoglycoside and NbKε-neamine. Then, I evaluate inhibition for TAR-Tat and 
RRE-Rev. 
 
 
 
Figure 1-12  Designed novel amino saccharides (neamine derivatives) 
 
 In chapter 2, I describe the development of the useful glycosylation method to 
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disaccharide compositions by the efficient dehydrative glycosylation reaction which used 
Bi(OTf)3. In chapter 2-2-2-1, I examined the optimal conditions for carrying out the 
self-condensation of these, using glucose, mannose, galactose, 2-N3-glucose, 
2-N3-6-OAc-glucose and arabinose as 1-hydroxy sugars. In chapter 2-2-2-2, I describe 
about the stereospecificity of non-reducing disaccharide formation.  
 In chapter 3, I describe about the synthetic approach to trehalosamine and aromatic 
aminoglycoside as the neamine mimics. In chapter 3−2−1, I describe about the synthesis 
of novel non-reducing amino disaccharides (trehalosamine). In chapter 3−2−2, I describe 
about the synthesis of aromatic modified amino saccharide (aromatic aminoglycoside).  
 In chapter 4, I describe the synthetic approach to nucleobase modified neamines with a 
lysine as a linker, nucleobase substituted on the ε-amino group of the amino acid 
(NbKε-namines) as the novel small compound expected to bind to the hairpin RNA 
specifically. 
 In chapter 5, I describe the evaluation of the “Trehalosamine” and “NbKε-neamine” as 
inhibitors of TAR-Tat and RRE-Rev. In chapter 5−2−1, I described the evaluation of the 
“Trehalosamine” and “NbKε-neamine” as inhibitors of TAR-Tat. In chapter 5−2−2, I 
describe the evaluation of the “NbKε-neamine” as inhibitors of RRE-Rev.  
 In chapter 6, finally I describe about the summary of this research. 
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Chapter 2  The development of novel dehydrative glycosidation to modify the  
           neamine scaffold 
 
2-1.  Introduction 
 In this chapter, I focused on the structure of non-reducing disaccharides that would be 
novel neamine analogs, and describe the development of the useful glycosylation 
method to construction of non-reducing disaccharides. 
 
2-1-1.  Structure of non-reducing disaccharides and their functions 
 The disaccharides of which condensed two mono saccharides at the anomeric hydroxyl 
groups are called non-reducing disaccharides. The trehalose composed of two glucose 
molecules is a typical example (Fig. 2-1). 
 
 
 
Figure 2-1  Structure of non-reducing disaccharides (trehalose)  
 
 Trehalose is broadly used in the fields of medical treatment, foods, and cosmetics, and 
its functions attract attention. Trehalose have three kinds of structural isomers, 
αα-conformation (trehalose), αβ-conformation (neotrehalose) and ββ-confor –mation 
(isotrehalose). Most naturally-occurring trehalose is αα-conformation. αα-Trehalose is 
metabolized into glucose by trehalase that is the catabolic enzyme. And trehalase is 
distributed over the internal organs of many organism species, such as a small intestine 
and the kidney.  
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 Trehalose is widely distributed over insects, mushrooms, shrimps, mold, yeast, red alga 
and the lichen. Especially in case of the plants, trehalose not only exists as the main 
saccharide, but it has an effect as an antifreeze agent, it is known that they have cold 
resistance. Furthermore, trehalose is used in various fields, such as cosmetics as a 
moisturizer, improving keeping of food and maintaining the freshness of vegetables or 
fruits. In this way, it is clear that trehalose have very attractive behaviors, such as the 
stabilization of the protein, the cytoprotective action from freeze and dryness and an 
effect as the moisturizer.1,2 Additionally, the preventive medicine of neurodegenerating 
diseases including Alzheimer's disease and a possibility that osteoporosis could be 
controlled were suggested to trehalose recently, and the derivatives of treharose as 
medical supplies are increasing.3,4 
 
 
 
Figure 2-2  Naturally-occurring non-reducing disaccharides 
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 It has been reported that the natural products having the non-reducing disaccharides 
unit have antibacterial and antiviral activity. Galactotrehalose is an analog of trehalose 
formed by replacing one of the glucose units by galactose. It is reported that 
galactotrehalose works as a ligand of the Shiga toxin produced by the Escherichia coli.5 
Trehalosamine is the other analog of trehalose in which the hydroxyl group at 
C’6-position is replaced to the amino group, and it is known that it is active against 
mycobacterium tuberculosis.6 Trehalose-6,6’-dimycolate has a trehalose as its skeleton 
to which the 6-hydroxyl groups are modified with lipids, it has antitumor activity and 
antimycobacterium tuberculosis activity.7 Tunicamycin which consists of 
N-acetylglucosamine and N-acylglactosamine derivative, has been reported as an 
antibiotic having the N-glycosylation inhibition (Fig. 2-2).8,9 
 Thus, the compounds that have non-reducing disaccharides structure have a number of 
useful functions and they play the important role for the life. In this study, I paid attention 
to this non-reducing disaccharide as a candidate of another scaffold which might 
replaceable with neamine. I describe in this chapter the development of the convenient 
synthetic route for the non-reducing disaccharides.  
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2-1-2.  Conventional method of the glycosylation for the synthesis of 
non-reducing disaccharides 
 
 Some synthetic methods of the non-reducing disaccharide have already reported.10,11 
However, a classical Koenig-Knorr method using Br or Cl as leaving group has only 
reported.10 Recently, it is reported that the yield was improved when trichloroacetimidate 
was used as a leaving group.11 However this method has serious problem. This method 
requires excessive amount of the activating reagent for leading intermediate such as 
glycosyl haride or glycosyl imidate before glycosylation reaction Since the glycosylation 
reaction is depends on the combination of the donor and the acceptor of the 
monosaccharide, the yield is relatively low (Scheme 2-1, 2-2). Although biochemical 
feasibility of non-reducing disaccharide was not clarified until recent years, the 
development of synthetic methodology had not well established.  
 
 
 
Scheme 2-1  Koenig-Knorr method 
 
 
 
Scheme 2-2  Imidate method 
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 Also the synthetic technique of non-reducing disaccharides without introducing a 
leaving group by dehydrative glycosidation of the two aldose sugars which have the 
anomer hydroxyl group (1-hydroxy sugar) was reported in recent years. Most of the 
synthetic methods of non-reducing disaccharide consist of two steps for introducing an 
appropriate leaving group, it is thought that dehydrative glycosylation without introducing 
a leaving group is the most convenient method in the synthesis of the symmetric 
non-reducing disaccharides that built from the same sugar. Furthermore, since the 
stability of 1-hydroxy sugar is high, it is an advantage for manufacture of a 
monosaccharide as a donor to be also easy. However, there are few examples that 
report the synthesis of non-reducing disaccharide using the dehydrative glycosylation. 
Due to the difficulty of the activation of the hydroxyl group at anomeric carbon is not easy. 
It has been reported the example using strong acid as catalysts, such as TMSOTf or 
Tf2O in surplus (Scheme 2-3).12,13 Therefore, if the reactivity of various 1-hydroxy sugars 
in dehydrative glycosylation can be raised, it might be applicable to the synthesis of the 
non-reducing disaccharide. 
 
 
 
Scheme 2-3  The dehydrative glycosylation using powerful acid catalysts 
 
 As mentioned above, it is worth study the development of the way of the efficient 
dehydrative glycosylation which activates 1-hydroxy sugar directly, and to make it apply 
to non-reducing disaccharide. 
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2-1-3.  Conventional dehydrative glycosylation methods 
 
 As described in Chapter 2-1-2, in order to attain effective synthesis of various 
non-reducing disaccharide, the development of the novel method for dehydrative 
glycosylation that directly activates 1-hydroxy sugar is required. 
 A glycosylation reaction transforms the donor of the sugar which has a suitable 
functional group for the anomeric position of the saccharide into an oxocarbenium 
cationic intermediate by an activator, and makes glycoside form, when the alcohol which 
is an acceptor saccharide attacks this. It is known that most of the glycosylation reaction 
is considered to proceed via SN1 reaction, and the reactivity greatly depend on the 
combination of a leaving group, the activator, the solvent, and the protecting group. 
Especially the combination of a leaving group and an activator is very critical. 
 When 1-hydroxy sugar was used for a sugar donor, the ability of leaving-group of an 
anomeric hydroxyl group is low, and transformation to an oxocarbenium cationic 
intermediate is not easy. However, recruitment of an appropriate activating reagent might 
solve this problem. The reagent activates an anomeric hydroxyl group effectively and 
turn it as leaving group. 
 Moreover, the dehydrative glycosylation reaction using 1-hydroxy sugar is considered 
as the most efficient synthetic method of non-reducing disaccharide because 1-hydroxy 
sugar works also as a sugar receptor. 
 On the other hand, the condensation reaction of a 1-hydroxy sugar and common 
alcohols, it is necessary to avoid condensation reaction of the 1-hydroxy 
monosaccharide by itself (Scheme 2-4). 
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Scheme 2-4  The dehydrative glycosylation reaction 
 
 Recently, several groups have reported the dehydrative glycosylation using the 
tetramethylsilylation14 and bromination15,16 of an anomeric hydroxyl group during the 
glycosylation reaction. However, more convenient method for the synthesis of 
non-reducing disaccharide is demanded (Scheme 2-5). 
 
 
 
Scheme 2-5  Conventional dehydrative glycosylation reactions 
 
+
Sn(OTf)3, TMS2O 
CaSO4
MeNO2
OH
O OH
BnO
BnO OBn
O
BnO
BnO OBn
O
OBnO
OAc
BnO
BnO
OH
+
PPh3, CBr4
DMF
Me
Me
Me
Me
Me
HO
OBnO
OAc
BnO
BnO MeMe
Me
Me Me
O
 
 
３１ 
 Our previous work showed that the O-ketopyranosidation17 via the dehydrative 
condensation of artificial ketopyranoses, i.e., 1-C-alkylated sugar derivatives, were 
obtained successfully when catalytic bismuth(III) triflate (Bi(OTf)3) as the activator was 
used (Scheme 2-6).18 
 
 
 
Scheme 2-6  Dehydrative glycosylation using 1-C-alkylated sugar derivatives 
 
 This finding made me try to synthesize dehydrative O-aldosylation by dehydrative 
glycosidation using Bi(OTf)3 as an activator.19 Then I have studied the direct synthesis of 
disaccharide with various O-glycosidic linkages start from 1-hydroxy sugars. 
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2-1-4.  Strategies to establish novel ways to the synthesis of non-reducing  
       disaccharides 
 
 As an aim to establish novel method for the synthesis of non-reducing disaccharides, 
we focused on Bi(OTf)3 as one of the useful activator in the dehydrative glycosylation. At 
first chapter 2-2-1, I developed the method in condensation for 1-hydroxy sugars with 
several alcohols. I have studied in detail about the conditions giving non-reducing 
disaccharides was obtained as a by-product while clarifying the reaction characteristic of 
1-hydroxy sugars (Scheme 2-7). 
 
 
 
Scheme 2-7  Dehydrative glycosylation using Aldose(1-Hydroxy sugar) 
 
 I have studied the synthesis of the various non-reducing disaccharides by the efficient 
dehydrative glycosylation reaction which used Bi(OTf)3 (Chapter 2-2-2-1). Then I had 
optimized the conditions for carrying out the self-condensation of 1-hydroxy sugars, 
glucose, mannose, galactose, 2-N3-glucose, 2-N3-6-OAc-glucose and arabinose 
(Scheme 2-8). Finally, we have examined the stereoselectivity of non-reducing 
disaccharides composition (Chapter 2-2-2-2). 
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Scheme 2-8  The synthetic strategy of non-reducing disaccharides 
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2-2.  Results and Discussion 
2-2-1. The development of novel dehydrative glycosidation 
     “The various reactions for 1-hydroxy sugars and alcohols” 
 
 In this chapter, we developed the condensation reaction of 1-hydroxy sugars with 
several alcohols in the presence of Bi(OTf)3. Also I investigated in detail about the 
conditions that gave non-reducing disaccharides as by-products while clarifying the 
reaction characteristic of 1-hydroxy sugars.20,21 
 
 The 1-hydroxy sugars and alcohols as glycosyl acceptors used in this study are shown 
in Figure 2-3 and 2-4. The typical O-glycosides and 1,1’-disaccharides produced are 
shown in Figure 2-5 and 2-6. 
 
 
Figure 2-3  1-hydroxy sugars used 
 
 
Figure 2-4  Alcohols used 
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Figure 2-5  Typical O-glycosides produced 
 
 
Figure 2-6  1-1’-Disaccharides produced 
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 I first investigated the glycosidation of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (1) with 
an equimolar amount of 2-phenylethyl alcohol (7). The amount of Bi(OTf)3 was varied in 
CH2Cl2 for 2 h at room temperature in the presence of anhydrous calcium sulfate 
(CaSO4) as a drying reagent. These reaction conditions were similar to those previously 
reported.22 The reaction using 5 mol% Bi(OTf)3 afforded the corresponding glycoside 
(12) in only 35% yield. The use of 10 mol% Bi(OTf)3 effectively promoted the 
glycosidation to produce 12 in a respectable yield of 85% with an α/β ratio of 71/29. It is 
noteworthy that under these reaction conditions the production of 1,1’-disaccharide (23) 
as a by-product decreased only to 7% as a yield. The use of 20 mol% Bi(OTf)3 slightly 
reduced the yield of 12 to 68% with an increase in the yield of 23 as a by-product to 13%. 
When the reaction temperature was raised to reflux, the glycosidation using only 5 mol% 
of Bi(OTf)3 in CH2Cl2 for 15 min easily proceeded to give the product 12 in a good yield of 
87% (α/β = 69/31) with the formation of 23 as a by-product in only 9% yield. A similar 
reaction using a mixed CH2Cl2/CH3CN (v/v = 1/2) solvent at reflux temperature gave 12 
in 72% yield (α/β = 34/66). The effect of other metal triflates was examined. Similar 
reaction conditions employing 5 mol% scandium(III) triflate (Sc(OTf)3) and ytterbium(III) 
triflate (Yb(OTf)3) afforded 12 in 82% yield (α/β = 65/35) and 14% yield (α/β = 44/56), 
respectively. Sc(OTf)3 was fairly effective in dehydrative glycosidation. Thus, a reaction 
using only 5 mol% Bi(OTf)3 at reflux temperature in CH2Cl2 for 15 min effectively 
promoted the glycosidation between 1 and 7 (1 equivalent) to produce the desired 12 
with only a slight production of 23 (Scheme 2-9, Table 2-1; Entry 1-7). 
 
 
 
Scheme 2-9  The formation of O-glycosides by the reaction of 1-4,6 with 7-11 
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Table 2-1  The formation of O-glycosides by the reaction of 1-4,6 with 7-11 
 
 
 Next, I examined the glycosidation of 1 with various alcohols (1 equivalent) using 5 
mol% Bi(OTf)3 at reflux temperature in CH2Cl2 for 15 min. A reaction using n-octanol (8) 
produced the glycoside 17 in a good yield of 85% (α/β = 62/38) with the production of 23 
in only 9% yield. The glycosylation of 1 to methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside 
(9) afforded 19 in a moderate yield of 52% (α/β = 75/25) with the production of 23 in 11% 
yield. Even reactions using less reactive acceptors such as phenol (10) and 
1-adamantanol (11) produced the corresponding glycosides 20 and 21 in 40% (α/β = 
1c Bi(OTf)3  (5) 35 (57 / 43)
87 (69 / 31)
4
9
2c
3d 68 (57 / 43) 13
4
85 (71 / 29) 7
72 (34 / 66) 175e
Entrya Activator (mol%) Yield / %
( α / β )b
Glycoside 1,1'-Disaccharide
aReaction conditions: molar ratio of donor : acceptor = 1 : 1; solvent = CH2Cl2; reflux temperature; reaction time = 15 min.
bAll the α/β ratios were determined by NMR. cReaction conditions: room temperature; reaction time = 12 h. 
dReaction conditions: room temperature; reaction time = 2 h. eThe mixed solvent (CH2Cl2/CH3CN = 1/2) was used. 
fReaction time = 40 min. gCompound 22 was obtained in 31% yield as a byproduct.
Bi(OTf)3  (5)
Bi(OTf)3  (5)
Bi(OTf)3  (10)
Bi(OTf)3  (20)
82 (65 / 35) 116 Sc(OTf)3  (5)
14 (44 / 56) 47f Yb(OTf)3  (5)
1-Hydroxy
sugar Alcohol Yield / %Product Product
1
1
1
1
1
1
1
7
7
7
7
7
7
7
12
12
12
12
23
23
23
23
23
23
23
12
12
12
85 (62 / 38) 98 Bi(OTf)3  (5)1 8 2317
52 (75 / 25) 119 Bi(OTf)3  (5)1 9 2319
40 (80 / 20) 2110g Bi(OTf)3  (5)1 10 2320
58 (65 / 35) 1711 Bi(OTf)3  (5)1 11 2321
73 (100 / 0) 1612 Bi(OTf)3  (5)2 7 2413
81 (91 / 9) 1613 Bi(OTf)3  (5)2 8 2418
70 (77 / 23) 1014 Bi(OTf)3  (5)3 7 2514
51 (52 / 48) 1515 Bi(OTf)3  (5)4 7 2615
81 (85 / 15) 516 Bi(OTf)3  (5)6 7 2816
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80/20) and 58% (α/β = 65/35) yields with the production of 23 in 21% and 17% yields, 
respectively. In addition, during the reaction using 10, the benzyl glucoside 22 was 
obtained as another byproduct in 31% yield. It seemed that the benzyl alcohol was 
formed along with the degradation of 1 under the reaction conditions using 10. The 
glycosidation of 1 with some primary alcohols afforded the desired glycosides in good 
yields. In contrast, for the reactions using less reactive alcohols such a benzyl alcohol, 
for example, the yields of the desired glycosides decreased due to increase in the yield 
of 23 and the appearance of a new byproduct 22 (Scheme2-9, Table 2-1; Entry 8-11). 
 Similar to 1, 2,3,4,6-tetra-O-benzyl-D-mannopyranose (2), 2,3,4,6-tetra-O-benzyl-D-gal 
-actopyranose (3), 2-azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (4) and 2,3,5-tri- 
O-benzyl-D-arabinofuranose (6) were used as 1-hydroxy sugars. The reaction of 2 with 7 
or 8 under the reaction conditions using 5 mol% Bi(OTf)3 at reflux temperature for 15 min 
afforded the corresponding glycosides with some stereoselectivity, 13 or 18 in 73% yield 
(α only) or 81% yield (α/β = 91/9) and the production of the 1,1’-disaccharide 24 in 16% 
yield in both cases. Similar reaction conditions using 3, 4, or 6 with 7 gave the glycosides 
14, 15 or 16 in 70% yield (α/β = 77/23), 51% yield (α/β = 52/48) or 81% yield (α/β = 
85/15) with the production of the 1,1’-disaccharide 25, 26 or 28 in 10%, 15% or 5% yield, 
respectively (Scheme2-9, Table 2-1; Entry 12-16). 
 
 This reaction is a competitive reaction of 7-11 with 1-4,6 which are also an acceptor, 
since 7-11 have nucleophilicity stronger than 1-4,6, it is thought that glycosides (12-21) 
ware obtained preferentially. Thus, since nucleophilicity of sugar alcohols like 1-4,6 is 
low, it was suggested that examination of the further conditions is required in order to 
compound non-reducing disaccharide. The postulated reaction mechanism is shown in 
Scheme 2-10. 
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Scheme 2-10  The mechanism of this dehydrative glycosylation 
 
 As I have discussed in this chapter, I have successfully developed the condensation 
reaction of 1-hydroxy sugars with several alcohols. The reactions of several benzylated 
1-hydroxy sugars with certain primary alcohols using only 5 mol% Bi(OTf)3 at reflux 
temperature in dichloromethane for 15 min successfully afforded the desired 
O-glycosides in good yields. These reaction conditions restrict the generation of 
undesired 1,1’-disaccharides. When bulky alcohol with low reactivity was used, 
generation of many kind of non-reducing disaccharide was observed. It is expected that 
non-reducing disaccharide is produced in good yield in the absence of alchohol. 
Moreover, when glucose, galactose, and arabinose were used, α-structure was 
preferentially acquired according to the influence of an anomeric effect. In addition, when 
mannose was used, it was shown clearly that glycoside denotes α-stereoselectivity as a 
result of the steric hindrance of the transition state. 
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2-2-2.  The development for the synthesis of non-reducing disaccharides by  
       dehydrative glycosidation 
2-2-2-1. The synthesis of symmetric non-reducing disaccharides from the  
       1-hydroxy sugars 
 
 In chapter 2-2-2-1, I have described about the synthesis of the various non-reducing 
disaccharides by the efficient dehydrative glycosylation reaction using Bi(OTf)3. I 
examined the other optimal conditions for carrying out the self-condensation of these, 
using glucose, mannose, galactose, 2-N3-glucose, 2-N3-6-OAc-glucose and arabinose 
as 1-hydroxy sugars.21 
 
 We investigated the formation of the symmetrical 1,1’-disaccharide 23 by the 
self-condensation of 1 in detail. The reactions using 5 mol% and 10 mol% Bi(OTf)3 at 
reflux temperature for 15 min promoted the self-condensation of 1 to produce 23 in 77% 
and 71% yields. At the same time, however, the benzylglucoside 22 was obtained as a 
by-product in 19% and 14% yields, respectively. The reaction using 5 mol% Bi(OTf)3 at 
room temperature for 15 h afforded 23 in only 12% yield without the production of 22. 
The use of 10 mol% Bi(OTf)3 at room temperature increased the yield of 23 to 85% with 
an αα/αβ/ββ isomer ratio of 53/33/14. The use of 50 mol% Bi(OTf)3 decreased the yield 
of 23 to 59% and increased the yield of 22 to 35%. Larger amount of Bi(OTf)3 seemed to 
promote the degradation of 1 (Scheme 2-11, Table 2-2; Entry 1-6). 
 
 
 
Scheme 2-11  The formation of 1,1’-disaccharides by the self-condensation of 1-6 
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Table 2-2  The Formation of 1,1’-disaccharides by the self-condensation of 1-6 
 
 
 We examined the effect of other metal triflates using Sc(OTf)3 and Yb(OTf)3. While 
Sc(OTf)3 was a fairly effective activator for the production of 23 in 67% yield, Yb(OTf)3 
was completely ineffective. This result roughly corresponded to that of entries 6 and 7 in 
Table 2-1. Subsequently, the synthesis of various symmetrical 1,1’-disaccharides 24, 25, 
26, 27 and 28 by the self-condensation of the 1-hydroxy sugars 2-6 was examined. 
Similar reaction conditions using 10 mol% Bi(OTf)3 in CH2Cl2 at room temperature for 3 
1c Bi(OTf)3  (5) 77
85 (53 / 33 / 14)
2d
3 12
4
71
84 (65 / 29 / 6)5
Entrya Activator (mol%)
Yield / %  ( αα / αβ / ββ )b
1,1'-Disaccharide
aReaction conditions: solvent = CH2Cl2; room temperature; reaction time = 1 d. bAll the isomer ratios were determined by NMR. 
cReaction conditions: reflux temperature; reaction time = 10 min; compound 22 was obtained in 19% yield as a byproduct. 
dReaction conditions: reflux temperature; reaction time = 10 min; compound 22 was obtained in 14% yield as a byproduct. 
eCompound 22 was obtained in 35% yield. fReaction conditions: room temperature; reaction time = 1 h. 
gReaction conditions: 0 oC; reaction time = 1 d. hReaction conditions: 0 oC; reaction time = 3.5 h.
Bi(OTf)3  (10)
Bi(OTf)3  (20)
Bi(OTf)3  (10)
Bi(OTf)3  (5)
596e Bi(OTf)3  (50)
67 (55 / 32 / 13)7 Sc(OTf)3  (20)
1-Hydroxy
sugar Product
1
1
1
1
1
1
1
23
23
23
23
23
23
23
−8 Yb(OTf)3  (20)1 23
85 (100 / 0 / 0)9f Bi(OTf)3  (10)2 24
70 (71 / 29 / 0)10g Bi(OTf)3  (10)3 25
−11 Bi(OTf)3  (20)4 26
2312 Bi(OTf)3  (50)4 26
53 (35 / 32 / 33)13 Bi(OTf)3  (100)4 26
1714 Bi(OTf)3  (50)5 27
24 (14 / 44 / 42)15 Bi(OTf)3  (100)5 27
93 (85 / 15 / 0)16h Bi(OTf)3  (10)6 28
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to 15 h successfully gave 24, 25 and 28 in good yields of 85% (αα only), 70% 
(αα/αβ/ββ= 71/29/0) and 93% (αα/αβ/ββ= 85/15/0) from 2, 3 and 6, respectively. 
However, the same reaction conditions were not applicable to self-condensation of 4. 
The reaction conditions using 100 mol% Bi(OTf)3 increased the yield of 26 up to 53% 
(αα/αβ/ββ= 35/32/33). In addition, when we use 6-O-Acetyl-2-azido-3,4-di 
-O-benzyl-2-deoxy-D-glucopyranose (5) which is introduced acetyl group at 6th hydroxyl 
group by acetolysis reaction23, in the presence of 100 mol% Bi(OTf)3, the yield of 27 
increased to 24% (αα/αβ/ββ= 14/44/42). The reason reduced reactivity is explained as 
the difficult desorption of the anomeric hydroxyl group, since the electron density of the 
pyranose ring is decreased by the azido group and an acetyl group. Although reactivity of 
the glycosidation decreased, the convenient formulation of the non-reducing 
disaccharide which introduced azido groups, such as 26 and 27 were successfully 
acquired (Scheme 2-11, Table 2-2; Entry 7-16). 
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2-2-2-2.  Discussions for stereoselectivity in the synthesis of non-reducing  
        disaccharides 
 
 In chapter 2-2-2-2, we considered the stereospecificity of non-reducing disaccharide 
formation. 
 
 
 
Figure 2-7  The αβ abundance ratio of various aldopyranoses 30 minutes after 
            dissolving in CD2Cl2 solvent  
 
 In order to study the stereospecificity of a dehydrative glycosydation reaction, the 
anomeric effect of 1-hydroxy sugar shoud be considered. I decided to examine αβ ratio 
of various 1-hydroxy sugars. The αβ ratio of 1-hydroxy sugar which estimated by 
1H-NMR 30 minutes after the starting material were dissolved in CD2Cl2. The results 
were summarized in Figure 2-7. Glucose, mannose, galactose, and 2-N3-glucose were 
converted to the corresponding non-reducing disaccharides in the αβ ratios of 92/8, 
81/19, 54/46, and 58/42, respectively. 
 In the synthesis of non-reducing disaccharides using 1-hydroxy sugar(1), the αβ ratio 
depend on the stereospecificity of the glycosylation reaction, then α-configuration of the 
compound was acquired preferentially. The reaction using 4 showed similarly αβ ratio of 
the product-4, and αα/αβ/ββ ratio was approximately 1/1/1. Also, the reaction using 2, 
since 2 has a benzyl group at the C2-position in the false axial side in a transition state, 
and it becomes the steric hindrance of the β side, the steric structure of the sugar donor 
is controlled to α conformation. Moreover, it is also considered that the steric structure of 
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the sugar acceptor was restricted to α structure, in order to tend to take 1,2-trans 
conformation since 2 has a benzyl group of the 2-position in the false axial side. When 
the reaction was start from 3, αα/αβ/ββ ratio of the non-reducing disaccharide was 
obtained about 71/29/0 (Figure 2-8). The stereospecificity of 3 is differrent from the 
abundance ratio shown in Figure 2-7, it is thought that αβ ratio of 3 is approximately 7/3, 
since anomerization is promoted in the presence of Bi(OTf)3. And it is expected that this 
αβ ratio of 3 was derived from the stereospecificity of non-reducing disaccharide. 
 
 
 
Figure 2-8  The αβ abundance ratio of 25 
 
 There are following three possible reason why ββ conformation of non-reducing 
disaccharide derived from 3 was not found. (1) Since it is the anomeric hydroxyl group of 
β conformation is easily removed, (2) due to the benzyl group of the 4-position is in the 
axial side, and it is surmised that (3) most of 3 which works as a acceptor of the 
saccharide is α-conformation (Figure 2-9). 
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Figure 2-9  The stereospecificity of 3 as a sugar acceptor  
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2-3.  Conclusion 
 
 In chapter 2, I focused on the structure of non-reducing disaccharides that could be a 
novel neamine mimic, and describe the development of the useful method for the 
glycosylation to construct non-reducing disaccharide. 
 In chapter 2-2-1, I developed the condensation reaction of 1-hydroxy sugars with 
several alcohols (7-11) in the presence of Bi(OTf)3. The reactions of several benzylated 
1-hydroxy sugars (1-4, 6) with certain primary alcohols (7-8) using only 5 mol% Bi(OTf)3 
at reflux temperature in CH2Cl2 for 15 min successfully afforded the desired O-glycosides 
in good yields. These reaction conditions restricted the production of undesired 
1,1’-disaccharides. When bulky alcohol (9-11) with low reactivity was used, several kind 
of non-reducing disaccharide was observed. In the absence of alcohols, it is expected 
that non-reducing disaccharide is produced in good yield. Moreover, when glucose, 
galactose, and arabinose were used, α-structure was preferentially acquired from the 
influence of an anomeric effect. In addition, when mannose was used, it was shown 
clearly that glycosilation reaction obtained α-stereoselectivity derived from the steric 
hindrance of the transition state. 
 In chapter 2-2-2, we considered the synthesis of the various non-reducing 
disaccharides by the efficient dehydrative glycosylation reaction which used Bi(OTf)3. In 
chapter 2-2-2-1, we examined the optimal conditions for carrying out the 
self-condensation of these, using glucose, mannose, galactose, 2-N3-glucose, 
2-N3-6-OAc-glucose and arabinose as 1-hydroxy sugars. The yield of self-condensation 
with 1-hydroxy sugars was promoted by 10-100 mol% Bi(OTf)3 at room temperature in 
CH2Cl2 for 18 h and produced various 1,1’-disaccharides. Then we successfully 
established convenient formulation of the non-reducing disaccharide which introduced 
azido groups, such as 26 and 29 which has convertible structure to neamine derivatives. 
In chapter 2-2-2-2, we considered the stereospecificity of non-reducing disaccharide 
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formation. 
 As described above, I have established the novel dehydrative glycosydation which is 
capable of building a 1,1’-disaccharide structure efficiently. 
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2-4.  Experimental Section 
 
 1H NMR (600 MHz) and 13C NMR (150 MHz) spectra were recorded on a JEOL 
ECA-600 spectrometer in CDCl3 using TMS as an internal standard. Optical rotations 
were recorded on a JASCO DIP-360 digital polarimeter. HRMS were obtained on a 
Mariner spectrometer (PerSeptive Biosystems Inc.). Preparative TLC was performed 
using Merck silica gel 60GF254. Column chromatography was conducted using silica gel 
60 N (40~50 μm, Kanto Chemical Co., INC.). Bi(OTf)3 was purchased from 
Sigma-Aldrich. All anhydrous solvents were purified according to standard methods. 
 
2-Phenylethyl 2,3,4,6-Tetra-O-benzyl-D-glucopyranoside(12) 
 To a stirred suspension of Bi(OTf)3 (5.4 mg, 0.0082 mmol) and 7 (20.3 mg, 0.17 mmol) 
in CH2Cl2 (3 mL) was added 1 (89.2 mg, 0.17 mmol) in the presence of anhydrous 
CaSO4 (ca. 100 mg) under an Ar atmosphere. The resulting mixture was stirred at reflux 
temperature for 15 min. The reaction was then quenched by the addition of a saturated 
aqueous NaHCO3 solution (5 mL). The reaction mixture was extracted with EtOAc, and 
the organic layer was washed with water and a saturated aqueous NaCl solution. After 
the organic layer was dried over Na2SO4, the solvent was evaporated under reduced 
pressure. The crude product was purified using a preparative silica gel TLC (PTLC; 
EtOAc/hexane = 1/3) to give the desired glycoside 12 (92.4 mg, 87%, α mixture of a and 
β anomers) as a colorless oil and 1,1’-disaccharide 23 (8.3 mg, 9%) as a colorless oil. 
1H NMR δ 2.92-2.99 (m, CH2CH2Phαβ), 3.99 (dd, J = 8.2 Hz, J = 8.9 Hz, H-3α), 
4.19-4.23 (m, CHaHbCH2Phβ), 4.41 (d, J = 7.6 Hz, H-1β), 4.77 (d, J = 3.4 Hz, H-1α) 
13C NMR δ 35.9, 36.2, 68.4, 68.7, 68.9, 70.1, 70.6, 73.1, 73.36, 73.41,74.6, 74.80, 74.82, 
74.9, 75.59, 75.60, 77.6, 77.8, 80.0, 81.9, 82.2, 84.6, 96.8 (C-1α), 103.6 (C-1β) 
HRMS (ESI, α/β mixture) m/z calcd for 667.3030 (C42H44O6+Na+), found 667.2993. 
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Octyl 2,3,4,6-Tetra-O-benzyl-D-glucopyranoside (17)  
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.1 mg, 0.0078 
mmol), 8 (20.2 mg, 0.16 mmol), and 1 (84.1 mg, 0.16 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 17 (PTLC; EtOAc/hexane = 1/3, 85.6 mg, 85%, a mixture of α and β 
anomers) as a colorless oil and 23 (7.1 mg, 9%). 
1H NMR δ 0.86-0.89 (m, CH3), 1.27-1.70 (m, (CH2)6), 3.40-3.47 (m, H-2β, H-5β, 
CHaHb(CH2)6CH3α), 3.51-3.69 (m, H-2α, H-4α, Ha-6α, CHaHb(CH2)6CH3α, H-3β, H-4β, 
Ha-6β, CHaHb(CH2)6CH3β), 3.72 (dd, J = 3.4 Hz, J = 10.3 Hz, Hb-6α), 3.73-3.75 (m, 
Hb-6β), 3.77-3.80 (m, H-5α), 3.95-3.99 (m, CHaHb (CH2)6CH3β), 3.99 (dd, J = 8.9 Hz, J = 
9.6 Hz, H-3α), 4.39 (d, J = 7.6 Hz, H-1β), 4.76 (d, J = 4.1 Hz, H-1α) 
13C NMR δ 14.1, 22.6, 26.11, 26.14, 29.18, 29.21, 29.3, 29.3, 29.4, 29.7, 31.8, 31.8, 68.2, 
68.5, 69.0, 70.0, 70.1, 73.1, 73.4, 73.4, 74.7, 74.8, 74.9, 75.0, 75.6, 75.6, 77.7, 77.9, 
80.1, 82.1, 82.2, 84.7, 96.8 (C-1α), 103.6 (C-1β) 
HRMS (ESI, α/β mixture) m/z calcd for 675.3656 (C42H52O6+Na+), found 675.3680. 
 
Methyl 6-O-(2,3,4,6-Tetra-O-benzyl-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-gluco 
-pyranoside (19)  
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.0 mg, 0.0076 
mmol), 9 (70.8 mg, 0.15 mmol), and 1 (82.4 mg, 0.15 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 19 (PTLC; EtOAc/hexane = 1/3, 77.7 mg, 52%, a mixture of α and β 
anomers) as a colorless oil and 23 (9.2 mg, 11%). 
1H NMR δ 3.25 (s, CH3β), 3.35 (s, CH3 α), 3.43 (dd, J = 3.4 Hz, J = 8.9 Hz, H-2’α), 
3.48-3.57 (m, H-2α, H-2’β), 3.94-4.01 (m, H-3’α, H-3α), 4.35 (d, J = 8.2 Hz, H-1’β), 
4.50-4.62 (m, H-1α, H-1 β), 4.98 (d, J = 4.1 Hz, H-1’α) 
13C NMR δ 97.2 (C-1’ αα), 97.9 (C-1αα), 98.0 (C-1βα), 103.7 (C-1’ βα) 
HRMS (ESI, α/β mixture) m/z calcd for 1009.4497 (C62H66O11+Na+), found 1009.4479. 
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Phenyl 2,3,4,6-Tetra-O-benzyl-D-glucopyranoside (20) 
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.4 mg, 0.0082 
mmol), 10 (15.6 mg, 0.16 mmol), and 1 (89.0 mg, 0.16 mmol) in CH2Cl2 (3 mL) gave 20 
(PTLC; toluene/EtOAc = 10/1, 40.3 mg, 40%, a mixture of α and β anomers) as a 
colorless oil, 23 (18.5 mg, 21%) as a colorless oil and 22 (32.2 mg, 31%) as a colorless 
oil. 
1H NMR δ 3.56 (dd, J = 2.1 Hz, J = 10.3 Hz, Ha-6α), 3.60-3.80 (m, H-2α, Hb-6α, H-2β, 
H-3β, H-4β, H-5β, Hab-6β, Hb-6β), 3.79 (dd, J = 8.9 Hz, J = 10.3 Hz, H-4α), 3.87-3.89 (m, 
H-5α), 4.21 (dd, J = 8.9 Hz, J = 9.4 Hz, H-3α), 5.01 (d, J = 7.6 Hz, H-1β), 5.48 (d, J = 3.4 
Hz, H-1α) 
13C NMR δ 68.2, 68.8, 70.8, 73.3, 73.4, 73.5, 75.02, 75.05, 75.11, 75.77, 75.78, 77.4, 
77.7, 79.7, 82.0, 84.7, 95.4 (C-1α), 101.6 (C-1β) 
HRMS (ESI, α/β mixture) m/z calcd for 639.2717 (C40H40O6+Na+), found 639.2693.  
 
1-Adamantyl 2,3,4,6-Tetra-O-benzyl-D-glucopyranoside (21) 
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.6 mg, 0.0085 
mmol), 11 (27.1 mg, 0.18 mmol), and 1 (89.9 mg, 0.17 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 21 (PTLC; EtOAc/hexane = 1/3, 65.2 mg, 58%, a mixture of α and 
β anomers) as a colorless oil and 23 (15.0 mg, 17%). 
1H NMR δ 1.56-2.17 (30H, m, 1-adamantyl), 3.42-3.50 (m, H-2β, H-4β, H-5β), 3.53 (dd, J 
= 4.1 Hz, J = 9.6 Hz, H-2α), 3.60-3.67 (m, Ha-6α, H-4α, Ha-6β, H-3β), 3.73 (dd, J = 2.1 
Hz, J = 11.0 Hz, Hb-6β), 3.76 (dd, J = 3.4 Hz, J = 10.3 Hz, Hb-6α), 4.00-4.03 (m, H-5α), 
4.01 (dd, J = 8.9 Hz, J = 9.6 Hz, H-3α), 4.70 (d, J = 7.6 Hz, H-1β), 5.28 (d, J = 3.4 Hz, 
H-1α) 
13C NMR δ 30.6, 30.7, 36.3, 36.3, 42.4, 42.8, 68.8, 69.5, 69.6, 72.8, 73.3, 73.4, 74.51, 
74.54, 74.9, 75.1, 75.3, 75.5, 75.7, 78.1, 78.2, 80.1, 82.1, 82.3, 85.1, 89.8 (C-1α), 96.2 
(C-1β) 
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HRMS (ESI, α/β mixture) m/z calcd for 697.3500 (C44H50O6+Na+), found 697.3538. 
 
2-Phenylethyl 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranoside (13) (Table 1, Entry 
13) 
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.7 mg, 0.0087 
mmol), 7 (21.3 mg, 0.17 mmol), and 2 (94.1 mg, 0.17 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 13 (PTLC; EtOAc/hexane = 1/3, 82.1 mg, 73%) as a colorless oil and 
24 (14.7 mg, 16%) as a colorless oil. [α]D22+30.5° (c 4.1, CHCl3) 
1H NMR δ 2.82 (2H, t, J = 6.9 Hz, CH2CH2Ph), 3.57-3.63 (2H, m, CHaHbCH2Ph, H-5), 
3.67 (1H, dd, J = 2.1 Hz, J = 11.0 Hz, Ha-6), 3.71-3.74 (2H, m, H-2, Hb-6), 3.84-3.88 (2H, 
m, CHaHbCH2Ph, H-3), 3.95(1H, t, J = 9.6 Hz, H-4), 4.84 (1H, d, J = 2.1 Hz, H-1) 
13C NMR δ 36.0, 68.1, 69.3, 71.8, 72.1, 72.5, 73.3, 74.7, 74.9, 74.9, 80.0, 97.7 (C-1, 
JC1-H1 = 168.3 Hz) 
HRMS (ESI) m/z calcd for 667.3030 (C42H44O6+Na+), found 667.3073. 
 
Octyl 2,3,4,6-Tetra-O-benzyl-D-mannopyranoside (18)  
 The same procedure used for the preparation of 12 using Bi(OTf)3 (5.3 mg, 0.0081 
mmol), 8 (21.1 mg, 0.16 mmol), and 2 (87.3 mg, 0.16 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 18 (PTLC; EtOAc/hexane = 1/3, 84.9 mg, 81%, a mixture of α and β 
anomers) as a colorless oil and 24 (13.5 mg, 16%). 
1H NMR δ 0.88 (t, J = 6.9 Hz, CH3α), 1.26-1.52 (m, CH2(CH2)6CH3), 3.35 (ddd, J = 2.8 Hz, 
J = 6.9 Hz, J = 9.6 Hz, CHaHb(CH2)6CH3α), 3.65 (ddd, J = 2.8 Hz, J = 6.9 Hz, J = 9.6 Hz, 
CHaHb(CH2)6CH3α), 3.72-3.80 (m, H-2α, H-5α, Ha-6α, Hb-6α), 3.91 (dd, J = 3.4 Hz, J = 
9.6 Hz, H-3α), 3.99 (t, J = 9.6 Hz, H-4α), 4.37 (d, J = 0.7 Hz, H-1β), 4.86 (d, J = 1.4 Hz, 
H-1α)  
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13C NMR δ 14.1, 14.5, 22.61, 22.63, 26.08, 26.12, 29.16, 29.24, 29.3, 29.4, 29.7, 31.8, 
67.6, 69.3, 69.7, 70.0, 71.3, 71.7, 72.1, 72.5, 73.3, 73.4, 73.5, 73.6, 74.8, 74.9, 75.0, 
75.1, 75.9, 80.3, 82.3, 97.8 (C-1α, JC1-H1 = 165.7 Hz), 101.7 (C-1β, J C1-H1 = 152.6 Hz) 
HRMS (ESI, α/β mixture) m/z calcd for 675.3656 (C42H52O6+Na+), found 675.3663. 
 
2-Phenylethyl 2,3,4,6-Tetra-O-benzyl-D-galacutopyranoside (14) 
 The same procedure used for the preparation of 12 using Bi(OTf)3 (4.6 mg, 0.007 
mmol), 7 (17.1 mg, 0.14 mmol), and 3 (75.9 mg, 0.14 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 14 (PTLC; EtOAc/hexane = 1/3, 63.6 mg, 70%, a mixture of α and β 
anomers) as a colorless oil and 25 (7.6 mg, 10%) as a colorless oil. 
1H NMR δ 2.91-2.97 (m, CH2CH2Ph), 3.92 (dd, J = 2.8 Hz, J = 9.6 Hz, H-3α), 4.03 (dd, J 
= 3.4 Hz, J = 9.6 Hz, H-2α), 4.15-4.19 (m, CHaHbCH2Phβ), 4.37 (d, J = 7.6 Hz, H-1β), 
4.83 (d, J = 3.4 Hz, H-1α) 
13C NMR δ 36.0, 36.2, 68.6, 68.8, 68.9, 69.2, 70.5, 73.0, 73.1, 73.2, 73.30, 73.36, 73.39, 
73.5, 74.4, 74.7, 75.0, 75.1, 76.5, 78.8, 79.5, 82.1, 97.4 (C-1α), 103.9 (C-1β) 
HRMS (ESI, α/β mixture) m/z calcd for 667.3030 (C42H44O6+Na+), found 667.3011. 
 
2-Phenylethyl 2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranoside (15) 
 The same procedure used for the preparation of 12 using Bi(OTf)3 (6.8 mg, 0.01 mmol), 
7 (24 μL, 0.2 mmol), and 4 (95.2 mg, 0.2 mmol) in CH2Cl2 (3 mL) gave the desired 
glycoside 15 (PTLC; EtOAc/hexane = 1/3, 59.5 mg, 51%, a mixture of α and β anomers) 
as a colorless oil and 26 (31.2 mg, 33%) as a colorless oil. 
1H NMR δ 2.92-2.99 (4H, m, CH2CH2Ph), 3.34 (dd, J = 3.4 Hz, J = 10.3 Hz, H-2α), 
3.84-3.88 (m, CHaHbCH2Phα), 3.95 (t, J = 9.6 Hz, H-3α), 4.12-4.16 (m, CHaHbCH2Phβ), 
4.27 (d, J = 7.6 Hz, H-1β), 4.93 (d, J = 3.4 Hz, H-1α) 
13C NMR δ 36.0, 36.2, 63.3, 66.4, 68.2, 68.6, 68.9, 70.6, 70.9, 73.4, 73.5, 74.8, 
75.0, 75.3, 75.5, 77.7, 78.2, 80.1, 83.1, 97.6 (C-1α), 102.1 (C-1β) 
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HRMS (ESI, α/β mixture) m/z calcd for 602.2625 (C35H37O5N3+Na+), found 602.2668. 
 
2-Phenylethyl 2,3,5-Tri-O-benzyl-D-arabinofuranoside (16) 
 The same procedure used for the preparation of 12 using Bi(OTf) 3 (7.9 mg, 0.012 
mmol), 7 (29.3 mg, 0.24 mmol), and 6 (101.2 mg, 0.24 mmol) in CH2Cl2 (3 mL) gave the 
desired glycoside 16 (PTLC; EtOAc/hexane = 1/3, 102.6 mg, 81%, a mixture of α and β 
anomers) as a colorless oil and 28 (4.5 mg, 5%) as a colorless oil. 
1H NMR δ 2.86 (t, J = 6.9 Hz, CH2CH2Phβ), 2.90 (t, J = 6.9 Hz, CH2CH2Phα), 3.42 (d, J = 
6.2 Hz, Ha-5β, Hb-5β), 3.57 (dd, J = 5.5 Hz, J = 11.0 Hz, Ha-5α), 3.57 (ddd, J = 2.8 Hz, J = 
6.9 Hz, J = 10.3 Hz, CHaHbCH2Phβ), 3.61-3.66 (m, CHaHbCH2Phα, Hb-5α), 3.87 (ddd, J = 
2.8 Hz, J = 6.9 Hz, J = 9.6 Hz, CHaHbCH2Phβ), 3.91 (dd, J = 2.8 Hz, J = 6.9 Hz, H-3α), 
3.97 (ddd, J = 2.8 Hz, J = 6.9 Hz, J = 9.6 Hz, CHaHbCH2Phα), 4.00 (d, J = 2.1 Hz, H-2α), 
4.03 (dd, J = 4.1, 6.9 Hz, H-2β), 4.07-4.11 (m, H-3β, H-4β), 4.13-4.16 (m, H-4α), 4.86 (d, 
J = 4.1 Hz, H-1β), 5.02 (s, H-1α) 
13C NMR δ 36.0, 36.1, 68.3, 68.4, 69.6, 71.8, 72.0, 72.25, 72.28, 72.5, 73.2, 73.3, 80.2, 
80.4, 83.3, 83.4, 84.2, 88.3, 100.4 (C-1β), 106.2 (C-1α) 
HRMS (ESI, α/β mixture) m/z calcd for 547.2455 (C34H36O5+Na+), found 547.2446. A 
part of α anomer was isolated. α Anomer: [α] D25
 +46.6° (c 4.1, CHCl3). 
 
2,3,4,6-Tetra-O-benzyl-D-glucopyranosyl 2,3,4,6-Tetra-O-benzyl-D-glucopyrano 
-side (23) 
 To a stirred solution of Bi(OTf) 3 (8.3 mg, 0.013 mmol) in CH2Cl2 (3 mL) was added 1 
(68.4 mg, 0.13 mmol) in the presence of anhydrous CaSO4 (ca. 100 mg) under an Ar 
atmosphere. The resulting mixture was stirred at room temperature for 1 d. The same 
procedure used for the preparation of 12 was followed. The crude product was purified 
using a preparative silica gel TLC (EtOAc/hexane = 1/3) to provide the desired 
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1,1’-disaccharide 23 (57.0 mg, 85%, a mixture of αα, αβ, and ββ isomers) as a colorless 
oil. 
1H NMR δ 3.36-3.38 (m, Ha-6αα), 3.48-3.54 (m, Hb-6αα, H-2αβ-β, H-5ββ), 3.53 (dd, J = 
7.6 Hz, J = 8.2 Hz, H-2ββ), 3.57-3.65 (2H, m, H-2αα, H-2αβ-α), 3.68 (1H, t, J = 9.6 Hz, 
H-4αα), 3.76 (dd, J = 7.6 Hz, J = 10.3 Hz, H-4αβ-α), 4.02 (1H, dd, J = 8.9 Hz, J = 9.6 Hz, 
H-3αα-α), 4.09 (1H, t, J 20= 9.6 Hz, H-3αβ-α), 4.15-4.17 (1H, m, H-5αα-α), 4.58 (1H, d, J 
= 7.6 Hz, H-1αβ-β), 4.90 (d, J = 8.2 Hz, H-1ββ), 5.16 (1H, d, J = 3.4 Hz, H-1αβ-α), 5.23 
(1H, d, J = 3.4 Hz, H-1αα-α) 
13C NMR δ 68.1, 68.9, 70.6, 73.5, 74.6, 74.97, 75.03, 75.6, 77.6, 77.7, 79.3, 81.7, 81.9, 
82.2, 84.6, 94.4 (C-1αα), 99.3 (C-1ββ), 99.4 (C-1αβ-α), 104.1 (C-1αβ-β) 
HRMS (ESI, isomer mixture) m/z calcd for 1085.4810 (C68H70O11+Na+), found 1085.4798. 
A part of ββ isomer was isolated. ββ Isomer: [α] D20
 +15.9° (c 0.42, CHCl3). 
 
2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl 2,3,4,6-Tetra-O-benzyl-α-D-mannopyra 
-noside (24) 
 A similar procedure as employed for the preparation of 23 by stirring both Bi(OTf) 3 
(12.5 mg, 0.019 mmol) and 2 (103.2 mg, 0.19 mmol) in CH3Cl3 (3 mL) at rt for 1 h gave 
the desired 1,1’-disaccharide 24 (PTLC; EtOAc/hexane = 1/3, 86.0 mg, 85%) as a 
colorless oil. [α] D25 +30.2° (c 0.88, CHCl3) 
1H NMR δ 3.53-3.56 (2H, m, H-5), 3.60 (2H, dd, J = 2.1 Hz, J = 3.4 Hz, H-2), 3.63 (2H, dd, 
J = 2.1 Hz, J = 11.0 Hz, Ha-6), 3.69-3.72 (4H, m, Hb-6, H-3), 3.97 (2H, dd, J = 9.6 Hz, J = 
10.3 Hz, H-4), 5.20 (2H, d, J = 2.1 Hz, H-1) 
13C NMR δ 69.0, 72.1, 72.4, 72.6, 73.5, 74.0, 74.6, 75.3, 79.5, 93.3 (C-1, JC1-H1= 167.5 
Hz) 
HRMS (ESI) m/z calcd for 1085.4810 (C68H70O11+Na+), found 1085.4823. 
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2,3,4,6-Tetra-O-benzyl-D-galactopyranosyl 2,3,4,6-Tetra-O-benzyl-D-galactopyrano 
-side (25) 
 A similar procedure as employed for the preparation of 23 by stirring both Bi(OTf) 3 (6.4 
mg, 0.0098 mmol) and 3 (52.9 mg, 0.098 mmol) in CH2Cl2 (3 mL) at 0 oC for 1 d gave the 
desired 1,1’-disaccharide 25 (PTLC; EtOAc/hexane = 1/3, 36.3 mg, 70%, a mixture of αα 
and αβ isomers) as a colorless oil. 
1H NMR δ 4.54 (1H, d, J = 7.6 Hz, H-1αβ-β), 5.20 (1H, d, J = 3.4 Hz, H-1αβ-α), 5.28 (2H, 
d, J = 4.1 Hz, H-1αα) 
13C NMR δ 93.5 (C-1αα), 99.8 (C-1αβ-α), 103.7 (C-1αβ-β) 
HRMS (ESI, isomer mixture) m/z calcd for 1085.4810 (C68H70O11+Na+), found 1085.4816. 
A part of αα isomer was isolated. αα Isomer: [α] D21
 +74.5° (c 0.81, CHCl3).  
 
2-Azido-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranosyl 2-Azido-3,4,6-tri-O-benzyl-2- 
deoxy-D-glucopyranoside (26) 
 A similar procedure as employed for the preparation of 23 by stirring both Bi(OTf) 3 
(142.5 mg, 0.22 mmol) and 4 (103.8 mg, 0.22 mmol) in CH2Cl2 (3 mL) at rt for 1 d gave 
the desired 1,1’-disaccharide 26 (PTLC; EtOAc/hexane = 1/3, 53.8 mg, 53%, a mixture 
of αα, αβ, and ββ isomers) as a colorless oil. 
1H NMR δ 4.33 (1H, d, J = 7.56 Hz, H-1αβ-β), 4.72 (1H, d, J = 8.25 Hz, H-1ββ), 5.17 (1H, 
d, J = 3.44 Hz, H-1αβ-α), 5.21 (1H, d, J = 3.44 Hz, H-1αα) 
13C NMR δ 95.4 (C-1αα), 97.6 (C-1αβ-α), 101.3 (C-1αβ-β), 103.5 (C-1ββ) 
HRMS (ESI, isomer mixture) m/z calcd for 955.4001 (C54H56O9N6+Na+), found 955.4026. 
 
2,3,5-Tri-O-benzyl-D-arabinofuranosyl 2,3,5-Tri-O-benzyl-D-arabinofuranoside (28)  
 A similar procedure as employed for the preparation of 23 by stirring both Bi(OTf) 3 
(15.8 mg, 0.024 mmol) and 6 (101.2 mg, 0.24 mmol) in CH2Cl2 (3 mL) at 0 oC for 3.5 h 
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gave the desired 1,1’-disaccharide 28 αα (PTLC; EtOAc/hexane = 1/2, 78.2 mg, 79%) as 
a colorless oil and 28 αβ (13.7 mg, 14%) as a colorless oil. 
αα Isomer: [α] D22
 +54.9° (c 3.9, CHCl3) 
1H NMR δ 3.61-3.64 (2H, m, Ha-5), 3.65-3.68 (2H, m, Hb-5), 3.94-3.96 (2H, m, H-3), 
4.10-4.11 (2H, m, H-2), 4.24-4.27 (2H, m, H-4), 5.50 (2H, s, H-1) 
13C NMR δ 69.7, 71.8, 72.1, 73.4, 81.2, 83.7, 87.9, 102.1 (C-1). 
HRMS (ESI) m/z calcd for 845.3660 (C52H54O9+Na+), found 845.3686. 
αβ Isomer: [α] D25
 +18.5° (c 0.69, CHCl3);  
1H NMR δ 3.56-3.63 (3H, m, Ha-5α, Hb-5α, Ha-5β), 3.67 (1H, dd, J = 6.2 Hz, J = 10.3 Hz, 
Hb-5β), 3.99 (1H, dd, J = 2.8 Hz, J = 6.2 Hz, H-3α), 4.10-4.15 (4H, m, H-2α, H-2β, H-3β, 
H-4β), 4.30-4.32 (1H, m, H-4α), 5.18 (1H, d, J = 3.4 Hz, H-1β), 5.20 (1H, s, H-1α) 
13C NMR δ 69.5 (C-5α), 71.7 (CH2Ph), 72.1 (CH2Ph), 72.2 (CH2Ph), 72.6 (CH2Ph), 72.7 
(C-5β), 73.1 (CH2Ph), 73.3 (CH2Ph), 80.8 (C-4β), 81.4 (C-4α), 83.58 (C-3α), 83.62 (C-2β 
or C-3β), 84.56 (C-2β or C-3β), 87.8 (C-2α), 99.5 (C-1β), 106.1 (C-1α) 
HRMS (ESI) m/z calcd for 845.3660 (C52H54O9+Na+), found 845.3659. 
 
6-O-Acetyl-2-Azido-3,4-di-O-benzyl-2-deoxy-D-glucopyranosyl-6’-O-acetyl-2’-azido
-3’,4’-di-O-benzyl-2’-deoxy-D-glucopyranoside (27) 
1H NMR (600 MHz, CDCl3): δ 2.02-2.05 (18H, m, COCH3), 4.40 (1H, d, J = 8.25 Hz, 
H-1αβ-β), 4.69 (1H, d, J = 7.6 Hz, H-1ββ), 5.11 (1H, d, J = 3.4 Hz, H-1αα), 5.17 (1H, d, J 
= 4.1 Hz, H-1αβ-α).   
13C NMR (150 MHz, CDCl3): δ 20.8 (COCH3), 93.4 (C-1αα), 97.4 (C-1ββ), 99.3 
(C-1αβ-α), 101.5 (C-1αβ-β), 170.6 (COCH3). 
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Chapter 3  Design and synthesis of novel amino saccharide mimicking neamine  
           backbone 
“The development of synthetic approach to non-reducing amino 
disaccharides (Trehalosamine) and aromatic modified amino saccharide 
(Aromatic aminoglycoside).” 
 
3-1.  Introduction 
 
 Some aminoglycosides, have a consensus structure, i.e., 4-O-(2,6-diamino-2,6-dideoxy 
-α-D-glucopyranosyl)-2-deoxystreptamine. This compound is named neamine. Neamine 
is common structural unit as aminoglycoside antibiotics. The discovery of the pathogens 
having aminoglycoside-resistant has triggered the synthetic study of non-natural type of 
novel aminoglycoside derivatives.1 One of the recent focuses is directed to the synthetic 
exploration of neamine-like small molecules.2 Due to diverse role of RNA, the 
development of small molecules which bind to the specific RNA might becoming a 
contemporary demand that provide novel drugs which is capable of combatting serious 
diseases that we are facing. A few groups have reported the synthesis of small 
molecules by mimicking neamine using carbohydrate3 and heterocyclic compounds.4 
However, most of the small molecules reported so far have indicated only a modest 
affinity and selectivity for RNA. Then I have designed non-reducing amino disaccharides 
(Trehalosamine) and aromatic modified amino saccharide (Aromatic aminoglycoside) as 
a novel neamine mimic as shown in Figure 3-1.  
 
 
６１ 
 
 
Figure 3-1  Trehalosamine and aromatic aminoglycoside as novel neamine mimics 
 
 In this chapter, I describe the synthetic approach to trehalosamine (3-2-1) and aromatic 
aminoglycoside (3-2-2).  
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3-2.  Results and Discussion 
3-2-1. The synthesis of novel non-reducing amino disaccharides (trehalosamine) 
 
 In chapter 3−2−1, I describe about the synthesis of novel non-reducing amino 
disaccharides (trehalosamine) as a neamine mimic. I have suggested the introduction of 
the azido group to the 6-position hydroxyl group of 6-O-Acetyl-2-azido-3,4-di-O-benzyl 
-2-deoxy-D-glucopy-ranosyl-6’-O-acetyl-2’-azido-3’,4’-di-O-benzyl-2’-deoxy-D-glucopyra
noside (27) and a way of removing protective groups. 
 The acetyl group of the 6-position of 27 was deacetylated in the MeOH using NaOMe, 
purified by thin-layer chromatography, and it gave the trehalosamine derivatives as three 
structural isomers (αα(29), αβ(30), ββ(31)) which the C6-position is free (Scheme 3-1). 
 
 
 
Scheme 3-1  Deacetylation of 27 
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 Then C6-position hydroxyl group of 29 is tosylated at 94% in a pyridine using Ts-Cl in 
the presence of Et3N, and the non-reducing disaccharide which has azido groups in the 
C6-position (33) was obtained at 85% using NaN3 (Scheme 3-2). 
 
 
 
Scheme 3-2  Introduction of the azido group to the C6-position hydroxyl groups of 29 
 
 Same as described above, C6-position hydroxyl group of 30 is tosylated at 75%, and 
the non-reducing disaccharide which has azido groups in the C6-position (35) was 
obtained at 76% (Scheme 3-3). 
 
 
Scheme 3-3  Introduction of the azido group to the C6-position hydroxyl groups of 30 
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 The compound 37 was synthesized with same manner as 33 and 35. Similarly, 
6-position hydroxyl group of 31 is tosylated at 46%, and the non-reducing disaccharide 
which has azido groups in the C6-position (37) was obtained at 94% (Scheme 3-4). At 
this time, it is thought that the yield of tosylation improved by examining reaction 
conditions, since the compound in which only one Ts basis was introduced was 
observed. 
 
 
 
Scheme 3-4  Introduction of the azido group to the 6-position hydroxyl group of 31 
 
 The azido groups and the benzyl groups of 33, 35, 37 were removed in the THF/H2O 
using Pd(OH)2 and CH3COOH, and it obtained the trehalosamine as three structural 
isomers (αα(38), αβ(39), ββ(40)) which have amino groups at the C2 and C6-positions 
(Scheme 3-5). Then the three non-reducing disaccharides introduced four amino groups 
were successfully obtained as neamine mimics. 
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Scheme 3-5  Consideration of deprotection 
 
 The yield of non-reducing disaccharide (27), synthesized with dehydrative glycosidation 
(described in Chap. 2) was low (Table 2-2 Entry 14 (17%), 15 (24%)). And so, when 
imidate was employed as a leaving group, the yield of compound 27 was obviously 
improved. Glycosyl imidate (41) was prepared in 98% yield from 5 using CCl3CN and 
DBU. When the glycosylation of 41 with 5 was carried out using TMSOTf in CH2Cl2 at -20 
oC for 1h, the desired non-reducing disaccharide 27 was obtained in 89% yield (Scheme 
3-6). This reaction is not convenient compared with a dehydrative glycosydation, since it 
requires two steps. However, the yield was obviously improved, and it is thought that this 
method is a useful for the low reactive 1-hydroxy sugars. 
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Scheme 3-6  The synthesis of non-reducing disaccharide using the imidate method  
 
 As describe above, I studied about introduction of the azido group and deprotection. 
And, the synthesis of novel non-reducing amino disaccharides (trehalosamine) as a 
neamine mimic was successfully achieved. In addition, the imidate method was also 
examined and the yield of glycosylation has been improved. Therefore, I succeeded in 
the composition of the novel small compound which is able to bind to hairpin RNA 
specifically. Then, I described the results of the binding affinity with RNAs in chapter 
5-2-1. 
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3-2-2. The synthesis of novel aromatic modified amino saccharide (aromatic  
      aminoglycoside) 
 
 In chapter 3−2−2, I describe about the synthesis of aromatic modified amino saccharide 
(Aromatic aminoglycoside) as a neamine mimic. Aromatic aminoglycoside (47) has an 
aromatic aglycone structure which replaces the 2-deoxystreptamine unit of neamine with 
2,4-diaminophenol, and it is expected to have aromatic π-π stacking effects to increase 
the RNA-binding affinities.5 There is only one report that described about the synthesis of 
an aromatic glycoside having more than one amino group in the monosaccharide 
moiety.6 The synthetic route for the preparation of 47 is shown in Scheme 3-7. One of the 
major hurdle for synthesizing was the formation of the α-glycosidic linkage. I decided to 
make the linkage by the glycosylation procedure using 41 and 42. Compound 42 was the 
glycosyl acceptor and 41 was the glycosyl donor. Compound 42 was prepared in 94% 
yield from 2,4-diaminophenol dihydrochloride using N-(benzyloxycarbonyloxy) 
succinimide in pyridine. When the glycosylation reaction of 41 with 42 was carried out 
using TMSOTf in CH2Cl2 at -20 °C for 6 h, the desired glycoside 43 was successfully 
obtained in 55% yield, and the glycosidic linkage of 43 was formed with an 
α-stereoselectivity. The α-stereoselectivity during the glycosidation would be explained 
by the effect of the acetyloxy group at C-6 position of 41. Deprotection of the C-6 position 
acetyl group of 43 was performed using NaOMe in MeOH to afford 44 in 70% yield. The 
introduction of a tosyl group into the C-6 position of 44 was carried out using TsCl in 
pyridine to provide 45 with quantitative yield. The following reaction of 45 with sodium 
azide in DMF at 60 °C quantitatively gave 46. However, aromatic aminoglycoside (47) 
could not be obtained by the hydrogenation of 46 which was the protected precursor of 
47. It is necessary to carry out more detailed examination about the conditions of of 
removal of the protection group.  
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Scheme 3-7  The synthesis of aromatic aminoglycoside 
 
 In conclusion, compound 46 which the precursor of the aromatic aminoglycoside (47) 
was successfully synthesized from N-acetyl-D-glucosamine and 1,3-diaminophenol 
based on the technique of the glycosylation. However, aromatic aminoglycoside (47), 
initially desired compound, could not be obtained by the hydrogenation of 46. It is 
necessary to make a consideration of more detailed examination about the conditions of 
deprotection. 
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3-3.  Conclusion 
 In this chapter, I described the synthetic approach to trehalosamine (3-2-1) and 
aromatic aminoglycoside (3-2-2) as the neamine mimics. 
 In chapter 3−2−1, I described about the synthesis of novel non-reducing amino 
disaccharides (trehalosamine). I studied about introduction of the azido group to the 
6-position hydroxyl group of 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-D-glucopy 
-ranosyl-6’-O-acetyl-2’-azido-3’,4’-di-O-benzyl-2’-deoxy-D-glucopyranoside (27) and the 
way of removing the protection group. And, I succeeded the synthesis of trehalosamine 
as three structural isomers (αα(38), αβ(39), ββ(40)) which the 2,6-position is NH2 in good 
yield. In addition, the synthetic route via imidate was also examined then yield of 
glycosylation has been improved. 
 In chapter 3−2−2, I describe about the synthesis of aromatic substituted amino 
saccharide (aromatic aminoglycoside). The precursor 46 of the aromatic aminoglycoside 
(47) was successfully synthesized from N-acetyl-D-glucosamine and 1,3-diaminophenol 
based on the glycosylation technique. However, aromatic aminoglycoside (47) could not 
be obtained by the hydrogenation. 
 Therefore, I describe the binding affinity and binding specificity of trehalosamine (three 
structural isomers αα(38), αβ(39), ββ(40)) toward some specific RNA fragment.  
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3-4.  Experimental Section 
 
 1H NMR (600 MHz) and 13C NMR (150 MHz) spectra were recorded on a JEOL 
ECA-600 spectrometer in CDCl3 using TMS as an internal standard. Optical rotations 
were recorded on a JASCO DIP-360 digital polarimeter. HRMS were obtained on a 
Mariner spectrometer (PerSeptive Biosystems Inc.). Preparative TLC was performed 
using Merck silica gel 60GF254. Column chromatography was conducted using silica gel 
60 N (40~50 μm, Kanto Chemical Co., INC.). Bi(OTf)3 was purchased from 
Sigma-Aldrich. All anhydrous solvents were purified according to standard methods. 
 
2-Azido-3,4-di-O-benzyl-2-deoxy-6-hydroxy-α-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-hydroxy-α-D-glucopyranoside (29) 
1H NMR (600 MHz, CDCl3): δ 3.49 (2H, dd, J = 4.1, 10.3 Hz, H-2), 3.68 (2H, dd, J = 8.9, 
9.6 Hz, H-4), 3.75-3.82 (4H, m, H-6a and H-6b), 3.94 (2H, dt, J = 2.8, 9.6 Hz, H-5), 4.04 
(2H, t, J = 9.6 Hz H-3), 5.11 (2H, d, J = 3.44 Hz H-1).    
13C NMR (150 MHz, CDCl3): δ 61.3 (C-6), 63.2 (C-2), 72.3 (C-5), 77.5 (C-4), 80.2 (C-3), 
93.2 (C-1). 
[α] D28.5 ＝ +91.3°（C = 1.545, CHCl3） 
HRMS(ESI): m/z calcd for C40H44N6O9Na+: 775.3062, found: 775.3047 
 
2-Azido-3,4-di-O-benzyl-2-deoxy-6-hydroxy-α-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-hydroxy-β-D-glucopyranoside (30) 
1H NMR (600 MHz, CDCl3): δ 3.37-3.42 (4H, m, H-2α, H-4α, H-4β, and H-5β), 3.44 (1H, 
d, H-2β), 3.48-3.51 (1H, m, H-3β), 3.53-3.59 (2H, m, H-6α-a and H-6α-b), 3.79 (1H, d, J 
= 12.4 Hz, H-6β-b), 3.83 (1H, d, J = 11.7 Hz, H-6β-a), 4.03 (1H, dd, J = 8.9, 9.6 Hz, H-3α), 
4.11-4.14 (1H, m, H-5α), 4.44 (1H, d, J = 7.6 Hz, H-1β), 5.14 (1H, d, J = 3.4 Hz, H-1α).  
 
 
７１ 
13C NMR (150 MHz, CDCl3): δ 61.9 (C-6β), 62.3 (C-6α), 63.4 (C-2α), 66.8 (C-2β), 72.4 
(C-5α), 76.4, 77.5, 78.8 (C-4α or C-4β or C-5β), 79.9 (C-3α), 83.1 (C-3β), 99.4 (C-1α), 
102.1 (C-1β). 
[α] D28.5 ＝ +22.1°（C = 4.345, CHCl3） 
HRMS(ESI): m/z calcd for C40H44N6O9Na+: 775.3062, found: 775.3090 
 
2-Azido-3,4-di-O-benzyl-2-deoxy-6-hydroxy-β-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-hydroxy-β-D-glucopyranoside (31) 
1H NMR (600 MHz, CDCl3): δ 3.37 (2H, td, J = 2.9, 3.3, 9.1 Hz, H-4), 3.45-3.49 (4H, m, 
H-2 and H-5), 3.64 (2H, dt, J = 2.9, 9.3 Hz, H-3), 3.72-3.75 (2H, m, H-6a), 3.86-3.88 (2H, 
d, J = 12.0 Hz, H-6b), 4.71 (2H, dd, J = 2.2, 5.3 Hz, H-1).  
13C NMR (150 MHz, CDCl3): δ 61.5 (C-6), 65.7 (C-2), 75.6 (C-4), 77.0 (C-3), 82.6 (C-5), 
98.2 (C-1).  
[α] D28.0 ＝ -10.9°（C = 1.835, CHCl3） 
HRMS(ESI): m/z calcd for C40H44N6O9Na+: 775.3062, found: 775.3066 
 
2-Azido-3,4-di-O-benzyl-2-deoxy-6-O-tosyl-α-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-O-tosyl-α-D-glucopyranoside (32) 
1H NMR (600 MHz, CDCl3): δ 2.41 (6H, s, S(OO)PhCH3), 3.43 (2H, ddd, J = 3.4, 4.1, 
10.3 Hz, H-2), 3.57 (2H, dd, J = 8.9, 10.3 Hz, H-4), 3.89 (2H, t, J = 9.6 Hz, H-3), 
4.03-4.05 (2H, m, H-5), 4.03-4.05 (2H, m, H-5), 4.15 (2H, d, J = 10.3 Hz, H-6a), 4.29 (2H, 
dd, J = 3.4, 7.6 Hz, H-6b), 4.89 (2H, d, J = 3.4 Hz, H-1).   
13C NMR (150 MHz, CDCl3): δ 63.0 (C-2), 68.0 (C-6), 70.0 (C-5), 77.3 (C-4), 80.2 (C-3), 
93.1 (C-1). 
[α] D22.0 ＝ +45.6°（C = 1.820, CHCl3） 
HRMS(ESI): m/z calcd for C54H56N6 O13S2Na+: 1083.3239, found: 1099.3237 
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2-Azido-3,4-di-O-benzyl-2-deoxy-6-O-tosyl-α-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-O-tosyl-β-D-glucopyranoside (34) 
1H NMR (600 MHz, CDCl3): δ 2.36 (12H, s, S(OO)PhCH3), 3.34-3.37 (2H, m, H-2α and 
H-2β), 3.40-3.42 (3H, m, H-5β, H-4β, and H-3β), 3.64 (1H, dd, J = 8.9, 10.3 Hz, H-4α), 
3.94 (1H, dd, J = 4.1, 11.0 Hz, H-6α-a), 3.98 (1H, dd, J = 8.9, 10.3 Hz, H-3α), 4.12-4.14 
(2H, m, H-5α and H-6β-α ), 4.19 (1H, dd, J = 2.1, 11.0 Hz, H-6α-b), 4.29 (1H, dd, J = 3.4, 
11.0 Hz, H-6β-b), 4.33 (1H, d, J = 8.2 Hz, H-1β), 5.08 (1H, d, J = 3.4 Hz, H-1α). 
13C NMR (150 MHz, CDCl3): δ 21.6 (S(OO)PhCH3), 63.0 (C-2α), 66.4 (C-2β), 68.0 
(C-6α), 68.1 (C-6β), 70.0 (C-5α), 73.0 (C-4β or C-5β), 76.4 (C-4β or C-5β), 77.0 (C-4α), 
80.0 (C-3α), 82.9 (C-3β), 99.2 (C-1α), 101.0 (C-1β). 
[α] D28.0 ＝ +22.9°（C = 0.700, CHCl3） 
HRMS(ESI): m/z calcd for C54H56N6 O13S2Na+: 1083.3239, found: 1099.3209 
 
2-Azido-3,4-di-O-benzyl-2-deoxy-6-O-tosyl-β-D-glucopyranosyl-2’-azido-3’,4’-di-O-
benzyl-2’-deoxy-6’-O-tosyl-β-D-glucopyranoside (36) 
1H NMR (600 MHz, CDCl3): δ 2.42 (6H, s, S(OO)PhCH3), 3.42-3.47 (8H, m, H-2, H-3, 
H-4, and H-5), 4.11 (2H, ddd, J = 2.1, 2.8, 11.0 Hz, H-6a), 4.20 (2H, d, J = 11.0 Hz, H-6b), 
4.63 (2H, dd, J = 3.4, 4.1 Hz, H-1).  
13C NMR (150 MHz, CDCl3): δ 21.7 (S(OO)PhCH3), 65.6 (C-2), 68.0 (C-6), 73.1 (C-4), 
76.5 (C-3), 82.7 (C-5), 96.8 (C-1). 
[α] D28.5 ＝ -10.8°（C = 1.115, CHCl3） 
HRMS(ESI): m/z calcd for C54H56N6 O13S2Na+: 1083.3239, found: 1099.3286 
 
2,6-Diazido-3,4-di-O-benzyl-2,6-dideoxy-α-D-glucopyranosyl-2’6’-diazido-3’,4’-di-O-
benzyl-2’6’-dideoxy-α-D-glucopyranoside (33) 
1H NMR (600 MHz, CDCl3): δ 3.37 (2H, dd, J = 4.8, 13.1 Hz, H-6a), 3.52 (2H, dd, J = 2.1, 
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13.1 Hz, H-6b), 3.51-3.60 (4H, m, H-2 and H-4), 3.98 (2H, dd, J = 8.9, 10.3 Hz, H-3), 
4.10-4.13 (2H, m, H-5), 5.16 (2H, d, J = 3.44 Hz H-1).    
13C NMR (150 MHz, CDCl3): δ 50.9 (C-6), 63.3 (C-2), 71.3 (C-5), 78.6 (C-4), 80.3 (C-3), 
93.4 (C-1). 
[α] D22.0 ＝ +100.4°（C = 1.125, CHCl3） 
HRMS(ESI): m/z calcd for C40H42N12O7Na+: 825.3192, found: 825.3224 
 
2,6-Diazido-3,4-di-O-benzyl-2,6-dideoxy-α-D-glucopyranosyl-2’6’-diazido-3’,4’-di-O-
benzyl-2’6’-dideoxy-β-D-glucopyranoside (35) 
1H NMR (600 MHz, CDCl3): δ 3.30 (1H, dd, J = 4.8, 13.1 Hz, H-6α-b), 3.36 (1H, dd, J = 
4.8, 13.7 Hz, H-6α-a), 3.45-3.50 (5H, m, H-2α, H-2β, H-3β, H-4β, and H-6β-a), 3.54-3.59 
(3H, m, H-4α, H-5β, and H-6β-b), 4.03 (1H, dd, J = 8.9, 10.3 Hz, H-3α), 4.16-4.19 (1H, m, 
H-5α), 4.46 (1H, dd, J = 2.8, 5.5 Hz, H-1β), 5.18 (1H, d, J = 3.4 Hz, H-1α).  
13C NMR (150 MHz, CDCl3): δ 50.8 (C-6α), 50.9 (C-6β), 63.4 (C-2α), 66.7 (C-2β), 71.7 
(C-5α), 74.7 (C-4β), 77.5, 78.5 (C-4α or C-5β), 79.9 (C-3α), 82.9 (C-3β), 99.1 (C-1α), 
101.8 (C-1β). 
[α] D27.0 ＝ +76.4°（C = 2.290, CHCl3） 
HRMS(ESI): m/z calcd for C40H42N12O7Na+: 825.3192, found: 825.3227 
 
2,6-Diazido-3,4-di-O-benzyl-2,6-dideoxy-β-D-glucopyranosyl-2’6’-diazido-3’,4’-di-O-
benzyl-2’6’-dideoxy-β-D-glucopyranoside (37) 
1H NMR (600 MHz, CDCl3): δ 3.30-3.37 (4H, m, H-6a and H-6b), 3.45-3.49 (4H, m, H-3, 
and H-4), 3.51-3.58 (4H, m, H-2 and H-5), 4.79 (2H, d, J = 8.3 Hz, H-1).    
13C NMR (150 MHz, CDCl3): δ 50.9 (C-6), 65.8 (C-2), 75.4 (C-5), 77.9 (C-4), 82.8 (C-3), 
96.8 (C-1).   
[α] D28.0 ＝ -18.8°（C = 0.640, CHCl3） 
HRMS(ESI): m/z calcd for C40H42N12O7Na+: 825.3192, found: 825.3150 
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6-O-Acetyl-2-azido-3,4-di-O-benzyl-1-O-(2,2,2-trichloroacetimidoyl)-2-deoxy-α-D-gl
ucopyranose (41) 
 To a stirred solution of 6-O-Acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranose 
(325 mg, 0.76 mmol) and in CH2Cl2 (2 mL) was added 2,2,2-trichloroacetonitrile (380 μL, 
3.8 mmol) and 1,8-diazabicyclo[5.4.0]undeca-7-ene (18 μL, 0.11 mmol) at 0 °C under Ar 
atmosphere. The above solution was stirred at 0 °C for 1 h, then concentrated and 
purified using a flash silica gel column chromatography (1:5 AcOEt-hexane) to give 41 
(426 mg, 98% yield) as a colorless oil.  
1H NMR (CDCl3): δ 2.01 (3H, s, CH3), 3.68 (1H, t, J = 9.6 Hz, H-4), 3.69 (1H, dd, J = 3.4 
Hz, J = 9.6 Hz, H-2), 4.05-4.08 (1H, m, H-5), 4.06 (1H, t, J = 9.6 Hz, H-3), 4.24 (1H, dd, J 
= 4.1 Hz, J = 12.4 Hz, H-6a), 4.30 (1H, dd, J = 2.1 Hz, J = 12.4 Hz, H-6b), 4.60 (1H, d, J 
= 11.0 Hz, CH2Ph), 4.88 (1H, d, J = 11.0 Hz, CH2Ph), 4.94 (2H, s, CH2Ph), 6.41 (1H, d, J 
= 3.4 Hz, H-1), 7.26-7.41 (10H, m, Ph), 8.74 (1H, s, NH)  
13C NMR (CDCl3): δ 20.7 (CH3), 62.2 (C-6), 63.1 (C-2), 71.7 (C-5), 75.3 (CH2Ph), 75.6 
(CH2Ph), 77.3 (C-4), 80.2 (C-3), 90.8 (CCl3), 94.5 (C-1), 128.1-137.4 (Ph), 160.7 
(OC(NH)), 170.5 (C=O) 
HRMS (ESI): m/z calcd for C24H25N4O6•Na+: 593.0732, found: 593.0721. 
 
2,4-Bis(benzyloxycarbonylamido)phenol (42) 
 To a stirred solution of 2,4-diaminophenol dihydrochloride (107 mg, 0.54 mmol) in 
pyridine (5 mL) was added N-(benzyloxycarbonyloxy)succinimide (402 mg, 1.6 mmol). 
After stirring for 18 h, a 30% citric acid solution (5 mL) was added to the reaction mixture. 
The resulting mixture was extracted with CH2Cl2 (5 mL), and the organic layer was 
washed with water and a sat. NaCl solution. After the organic layer was dried over 
anhydrous Na2SO4, the solvent was filtered and evaporated under reduced pressure. 
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The crude product was purified using a preparative silica gel TLC (1:7 AcOEt-benzene) 
to give 42 (200 mg, 94% yield) as a white solid. mp 172-174 °C 
1H NMR (DMSO): δ 6.51 (2H, s, CH2), 6.55 (2H, s, CH2), 8.14-9.25 (13H, m, Ph) 
13C NMR (DMSO): δ 66.9 (CH2), 67.4 (CH2), 112.6-143.7 (Ph), 154.9 (C=O), 155.6 
(C=O). 
 
Dibenzyl 4-(6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyloxy) 
-1,3-phenylenedicarbamate (43) 
 To a stirred solution of 42 (173 mg, 0.44 mmol) and 41 (167 mg, 0.29 mmol) in CH2Cl2 
(4 mL) was added TMSOTf (53 μL, 0.29 mmol) in the presence of anhydrous CaSO4 (ca. 
100 mg) at -20 °C under Ar atmosphere. After the reaction mixture was stirred for 6 h, the 
reaction was then quenched by addition of a sat. NaHCO3 solution (5 mL). The reaction 
mixture was extracted with CH2Cl2 (5 mL), and the organic layer was washed with water 
and a sat. NaCl solution. After the organic layer was dried over anhydrous Na2SO4, the 
solvent was filtered and evaporated under reduced pressure. The crude product was 
purified using a preparative silica gel TLC (1:2 AcOEt-hexane) to give 43 (129.5 mg, 
55% yield) as a colorless oil.  
[α] D25.0 = +43° (c 2.4, CHCl3) 
1H NMR (CDCl3): δ 2.16 (3H, s, CH3), 3.61 (1H, dd, J = 8.9 Hz, J = 9.6 Hz, H-4), 3.69 (1H, 
dd, J = 4.1 Hz, J = 9.6 Hz, H-2), 4.11 (1H, dd, J = 8.9 Hz, J = 9.6 Hz, H-3), 4.20-4.23 (1H, 
m, H-5), 4.26 (1H, dd, J = 5.5 Hz, J = 11.7 Hz, H-6a), 4.36 (1H, dd, J = 2.1 Hz, J = 11.7 
Hz, H-6b), 5.01 (1H, d, J = 4.1 Hz, H-1), 6.95-8.09 (22H, m, Ph, H-5’ or H-6’), 7.03 (1H, d, 
J = 8.2 Hz, H-5’ or H-6’) 
13C NMR (CDCl3): δ 20.7 (CH3), 62.6 (C-6), 64.1 (C-2), 66.9 (CH2Ph), 70.3 (C-5), 75.1 
(CH2Ph), 75.8 (CH2Ph), 77.8 (C-4), 81.0 (C-3), 99.6 (C-1), 120.1 (C-5’ or C-6’), 
127.9-137.2 (Ph, C-5’ or C-6’), 153.2 (C=O), 163.6 (C=O), 170.6 (C=O) 
HRMS (ESI): m/z calcd for C44H43N5O10•Na+: 824.2902, found: 824.2869. 
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Dibenzyl 4-(2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyloxy)-1,3-pheny 
-lenedicarbamate (44) 
 To a solution of 43 (62 mg, 0.077 mmol) in MeOH (20 mL)-CH2Cl2 (0.5 mL) were added 
a 28% sodium methylate methanol solution (0.3 mL, 0.0016 mmol) at rt. After stirring 1.5 
h, water (5 mL) was added to the reaction mixture. The resulting mixture was extracted 
with AcOEt (5 mL), and the organic layer was washed with water and brine. After the 
organic layer was dried over anhydrous Na2SO4, the organic solvent was filtered and 
evaporated under reduced pressure. The crude product was purified using a preparative 
silica gel TLC (1:1 AcOEt-hexane) to give 44 (41 mg, 70% yield) as a colorless oil. 
[α] D27.0 = +41° (c 1.5, CHCl3) 
1H NMR (CDCl3): δ 3.65 (1H, dd, J = 3.4 Hz, J = 9.6 Hz, H-2), 3.72 (1H, t, J = 9.6 Hz, 
H-4), 3.79 (1H, bd, J = 11.7 Hz, H-6a), 3.88 (1H, bd, J = 12.4 Hz, H-6b), 4.02-4.09 (1H, m, 
H-5), 4.11 (1H, t, J = 9.6 Hz, H-3), 4.99 (1H, d, J = 3.4 Hz, H-1), 6.95-8.09 (22H, m, Ph, 
H-5’ or H-6’), 6.98 (1H, d, J = 8.2 Hz, H-5’ or H-6’) 
13C NMR (CDCl3): δ 61.2 (C-6), 64.2 (C-2), 66.9 (CH2Ph), 72.6 (C-5), 75.1 (CH2Ph), 75.8 
(CH2Ph), 77.5 (C-4), 80.8 (C-3), 99.8 (C-1), 120.3 (C-5’ or C-6’), 127.8-137.6 (Ph, C-5’ or 
C-6’), 153.1 (C=O), 153.2 (C=O) 
HRMS (ESI): m/z calcd for C42H41N5O9•Na+: 782.2796, found: 782.2776. 
 
Dibenzyl 4-(2-azido-3,4-di-O-benzyl-2-deoxy-6-O-tosyl-α-D-glucopyranosyloxy)-1,3 
-phenylenedicarbamate (45) 
 To a solution of 44 (40 mg, 0.053 mmol) and TsCl (201 mg, 1.1 mmol) in pyridine (5 mL) 
was added Et3N (147 μL, 1.1 mmol) at rt. After stirring for overnight, a solution of 30% 
citric acid (5 mL) was added to the reaction mixture. The resulting mixture was extracted 
with CH2Cl2 (5 mL). After the organic layer was dried over anhydrous Na2SO4, the 
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solvent was filtered and evaporated under reduced pressure. The crude product was 
purified using a preparative silica gel TLC (1:2 AcOEt-hexane) to give 45 (48 mg, 
quantitative yield) as a colorless oil. 
[α] D25.0 = +40° (c 1.2, CHCl3) 
1H NMR (CDCl3): δ 2.40 (3H, s, CH3), 3.61 (1H, dd, J = 3.4 Hz, J = 9.6 Hz, H-2), 3.64 (1H, 
t, J = 8.9 Hz, H-4), 4.05 (1H, t, J = 9.6 Hz, H-3), 4.10-4.14 (1H, m, H-5), 4.24 (1H, bd, J = 
10.3 Hz, H-6a), 4.29 (1H, dd, J = 4.1 Hz, J = 11.0 Hz, H-6b), 4.94 (1H, d, J = 3.4 Hz, H-1), 
6.67-8.02 (24H, m, Ph, H-5’ or H-6’), 6.86 (1H, d, J = 8.9 Hz, H-5’ or H-6’) 7.77 (2H, d, J = 
7.6 Hz, SO2C6H4) 
13C NMR (CDCl3): δ 21.6 (CH3), 63.9 (C-2), 66.9 (CH2Ph), 67.7 (C-6 and CH2Ph), 70.1 
(C-5), 75.1 (CH2Ph), 75.8 (CH2Ph), 77.2 (C-4), 80.7 (C-3), 99.6 (C-1), 119.9 (C-5’ or 
C-6’), 127.8-137.2 (Ph, C-5’ or C-6’), 152.7 (C=O), 153.1 (C=O) 
HRMS (ESI): m/z calcd for C49H47N5O11•Na+: 936.2885, found: 936.2877. 
 
Dibenzyl 4-(2,6-azido-3,4-di-O-benzyl-2,6-dideoxy-α-D-glucopyranosyloxy)-1,3 
-phenylenedicarbamate (46) 
 To a solution of 45 (45 mg, 0.049 mmol) in DMF (5 mL) was added NaN3 (16 mg, 0.24 
mmol). After stirring at 60 °C for 8 h, water (5 mL) was added to the reaction mixture. The 
resulting mixture was extracted with EtOAc (5 mL). After the organic layer was dried over 
anhydrous Na2SO4, the solvent was filtered and evaporated under reduced pressure. 
The crude product was purified using a preparative silica gel TLC (1:3 AcOEt-hexane) to 
give 46 (39 mg, quantitative yield) as a colorless oil. 
[α] D25.0 = +52° (c 0.91, CHCl3) 
1H NMR (CDCl3): δ 3.40 (1H, dd, J = 5.5 Hz, J = 13.1 Hz, H-6a), 3.57 (1H, dd, J = 2.7 Hz, 
J = 13.1 Hz, H-6b), 3.64 (1H, dd, J = 8.9 Hz, J = 9.6 Hz, H-4), 3.70 (1H, dd, J = 3.4 Hz, J 
= 9.6 Hz, H-2), 4.09 (1H, t, J = 9.6 Hz, H-3), 4.13-4.15 (1H, m, H-5), 5.05 (1H, d, J = 3.4 
Hz, H-1), 6.69-8.05 (22H, m, Ph, H-5’ or H-6’), 7.04 (1H, d, J = 8.2 Hz, H-5’ or H-6’) 
 
 
７８ 
13C NMR (CDCl3): δ 51.0 (C-6), 64.1 (C-2), 66.9 (CH2Ph), 71.7 (C-5), 75.2 (CH2Ph), 75.9 
(CH2Ph), 78.4 (C-4), 80.7 (C-3), 99.7 (C-1), 120.0 (C-5’ or C-6’), 127.7-137.4 (Ph, C-5’ or 
C-6’), 153.1 (C=O), 153.2 (C=O) 
HRMS (ESI): m/z calcd for C42H40N8O8•Na+: 807.2861, found: 807.2892. 
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Chapter 4  Design and synthesis of novel nucleobase modified neamines 
4-1.  Introduction 
4-1-1. Nucleobase modified neamines with a lysine or an arginine as a linker, 
     nucleobase substituted on the α-amino group of the amino acid. 
 
 On the binding of aminoglycoside antibiotics (Figure 1-8) to the A-site of 16S rRNA, it 
was reported that 6’-amino group of the compound is necessary.1 However modified 
neamine at 6’-amino group bound to either TAR or RRE RNA.2,3,4 Therefore, our group 
have been focusing on the modification at the 6’-amino group of neamine. Then, we have 
chosen TAR and RRE RNA as the targets and designed compounds that having an 
adenine (Ab), a cytosine (Cb), a guanine (Gb) or a thymine (Tb) at the 6’-amino group 
with L-lysine (NbKα-neamine) or L-arginine (NbRα-neamine) as the linker (Figure 4-1). 
 
 
 
Figure 4-1  Nucleobase modified neamines with a lysine or an arginine as a linker,  
           nucleobase substituted on the α-amino group of the amino acid. 
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 For the evaluation of the NbKα-neamine and NbRα-neamine as the binding inhibitor for 
TAR RNA, fluorescently labeled Tat peptide, FTatRhd5 was employed as the binding 
tracer (the detailed method for the evaluation of the binding is described in 5-1-2). The 
dissociation constants (Kd) of those neamine derivatives are summarized in Table 1. No 
matter what kind of nucleobase, modified neamines with lysine as a linker have 1.7-1.9 
µM as dissociation constants. These Kd values were 10 times smaller than that of 
lysine-modified neamine (K-neamine, Kd = 19 µM) and 16 times smaller than that of 
neamine. These results suggest that the nucleobase moiety in the neamine derivatives 
can not interact with specific base in the RNA when the nucleobase was introduced at 
the α-amino group of the linker amino acid. The Kd of arginine-modified neamine 
(R-neamine) was 0.60 µM. On the other hand, nucleobase-modified neamines with 
arginine as a linker have 0.25-0.54 µM as Kd. These results were very close to that of 
R-neamine, and 100 times smaller than that of neamine itself (Table 4-1).2  
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Table 4-1  Dissociation constants(Kd) of the neamine, K-neamine, NbKα-neamine  
           R-neamine and NbRα-neamine for TAR RNA 
 
Compounds Kd (µM) 
Neamine   28 
K-Neamine   19 
AbKα-Neamine    1.8 
CbKα-Neamine    1.9 
GbKα-Neamine    1.8 
TbKα-Neamine 
R-Neamine 
AbRα-Neamine 
CbRα-Neamine 
GbRα-Neamine 
TbRα-Neamine 
   1.7 
   0.60 
   0.29 
   0.29 
   0.25 
   0.54 
 
 As described above, It was revealed that the binding affinities of neither NbKα-neamine 
nor NbRα-neamine for TAR depended on the nucleobases. Therefore, in this study, I 
have decided that the nucleobase is introduced at the ε-amino group of the L-lysine 
(NbKε-neamine). 
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4-1-2. Nucleobase modified neamines with a lysine as a linker, nucleobase 
     substituted on the ε-amino group of the amino acid. 
 
 Nucleobase modified neamine at the C6-amino group of the neamine with lysine as a 
linker via conjugation at the ε-amino group of the lysine (NbKε-neamines) were designed 
which have an adenine (Ab), a cytosine (Cb), a guanine (Gb) or a thymine (Tb) (Figure 
4-2). An appropriate distance between the nucleobase and the neamine might make 
difference of binding affinity that depend on the nucleobase.  
 
 
 
Figure 4-2  Nucleobase modified neamines with a lysine as a linker, nucleobase  
           substituted on the ε-amino group of the amino acid. 
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4-2.  Results and Discussion 
     Synthesis of adenine, guanine, cytosine and thymine-Kε-neamine 
 
 In chapter 4−2, I describe about the synthesis of adenine(Ab), guanine(Gb), 
cytosine(Cb) and thymine(Tb)-Kε-Neamine as a novel nucleobase modified neamine. 
The nucleobases conjugated acetic acid (N6-Cbz-adenine-9-yl)-, (N4-Cbz-cytosine-1-yl)-, 
and thymine-1-yl-acetic acid (48, 49, and 50, respectively) were prepared by a previously 
reported method.6 These purine or pyrimidine derivatives (48-51) were introduced to the 
ε-amino group of lysine via amide bond using PyBrOP as a coupling reagent and in the 
presence of DIEA in DMF at r.t. for 18 hours, the desired compounds (52-55) were 
successfully obtained in 55-82% yield. After deprotection of the α-carbonyl group, 
nucleobase conjugated lysine unit (56-59) was introduced to the 6’-amino group of the 
neamine by the condensation reaction using WSC as a coupling reagent in DMF-H2O at 
room temperature for 18 hours, the desired glycosides (60-63) were successfully 
obtained in 5-25% yield. Finally, after all the protective groups were removed, the 
compounds were purified by reversed phase HPLC and characterized by 
MALDI-TOFMS and 1H NMR (Scheme 4-1). 
 Then the four novel nucleobase modified neamine with L-lysine as the linker 
(NbKε-neamine, 64-67) were successfully obtained as the novel small compound 
expected to bind to the hairpin RNA specifically. 
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Scheme 4-1  Synthetic route of nucleobase modified neamines (NbKε-neamines) 
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4-3.  Conclusion 
 
 In this chapter, I described the synthetic approach to nucleobase modified neamines 
with a lysine as a linker, nucleobase substituted on the ε-amino group of the amino acid 
(NbKε-namines).  
 NbKε-neamines having an adenine (Ab), a cytosine (Cb), a guanine (Gb) or a thymine 
(Tb) at the 6’-amino group with L-lysine as the linker were designed. The nucleobase 
was introduced at the ε-amino group of the L-lysine, due to the binding affinities for TAR 
were no difference when the nucleobase was conjugated to the α-amino group of lysine 
or an arginine as a linker. An appropriate distance between the nucleobase and the 
neamine might clarify the binding specificity derived from the difference of nucelobases. 
Then the four novel nucleobase modified neamine with L-lysine as the linker 
(NbKε-neamine, Ab(64), Cb(65), Gb(66), Tb(67)) were successfully obtained as the 
novel small compound expected to bind to the hairpin RNA specifically. 
 Then, I will describe about the binding affinity and binding specificity of four 
NbKε-neamine, ((Ab(64), Cb(65), Gb(66), Tb(67)) toward RNA fragments derived from 
HIV-1 activator region. 
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4-4.  Experimental Section 
 
 Amino acids were purchased either from Novabiochem or Kokusan Chemical Co., Ltd. 
All other chemicals were from Wako Pure Chemicals. HPLC was carried out with 
HITACHI L7100 pump and L7400 UV detector on YMC-Pack Pro C18 RS column. 1H 
NMR spectra were recorded with a JEOL JNM-LA300 or JNM-ECS400 spectrometer. 
Mass spectra were recorded with Shimadzu Axima CFR plus. 
 
Neamine 
 Neamine was obtained by the hydrolysis of neomycin7 and the counter ion chlorine was 
removed by ion exchange chromatography with Sephadex QAE A-25 
 
Nucleobase-conjugated amino acids 
 For the conjugation of the nucleobase unit with lysine, an acetic acid unit was 
introduced to the nucleobase unit. This unit was then conjugated to the amino acid by the 
con- densation reaction. Nucleobase-acetic acid derivatives (N6-Cbz-adenine-9-yl)-, 
(N4-Cbz-cytosine-1-yl)-, guanine-1-yl-acetic acid, and thymine-1-yl-acetic acid (48, 49, 
50, and 51, respectively), were prepared according to the previously reported method.8 
 
Methyl-αN-(benzyloxycarbonyl)-εN-[[6-N-(benzyloxy carbonyl)-adenine-9-yl]acetyl] 
lysinate (Cbz-Lys(Cbz(Cbz-Lys(Cbz-Ab -OMe))))  (52) 
 To a stirred suspension of 48 (0.101 g, 0.309 mmol) in DMF (3.0 ml) was added 
Cbz-Lys-OMe HCl (0.0771 g, 0.233 mmol). After cooling to 0 °C, to this suspension was 
added a solution of PyBrOP (0.174 g, 0.373 mmol) in DMF (1.0 ml) and DIEA (0.160 ml, 
0.904 mmol) in small portion. After stirring for 2 h in an ice bath, the reaction mixture was 
stirred for another 19 h at room temperature. The reaction mixture was poured into cold 
water (60 ml) and stored in a refrigerator overnight. The precipitate was collected on the 
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filter, washed with water, and dried in vacuum. The desired product 52 was obtained as a 
white powder (0.0989 g, 0.164 mmol, yield 70.0%). 
Rf = 0.80 (CHCl3/MeOH = 3/2) 
1H NMR (in d6-DMSO, 300 MHz) δ 10.7 (br s, 1H), 8.59 (s, 1H), 8.37 (s, 1H), 8.35 (t, 1H), 
7.73 (d, 1H), 7.75-7.29 (m, 10H), 5.22 (s, 2H), 5.04 (s, 2H), 4.92 (s, 2H), 4.01 (q, 1H), 
3.63 (s, 3H), 3.07 (q, 2H), 1.64 (m, 2H), 1.39 (m, 4H). 
 
Methyl αN-(benzyloxycarbonyl)-εN-[[4-N-(benzyloxycar -bonyl)-cytosine-1-yl] 
acetyl]lysinate (Cbz-Lys(Cbz-Cb) -OMe)  (53) 
 To a stirred suspension of 49 (0.240 g, 0.791 mmol) in DMF (7.8 ml) was added 
Cbz-Lys-OMe HCl (0.175 g, 0.527 mmol). After cooling to 0 °C, to this suspension was 
added a solution of PyBrOP (0.282 g, 0.633 mmol) in DMF (7.8 ml) and DIEA (0.360 ml, 
2.10 mmol) in small portion. After stirring for 2 h in an ice bath, the reaction mixture was 
stirred for another 22 h in room temperature. The reaction mixture was poured into cold 
water (100 ml) and stored in a refrigerator overnight. The precipitate was collected on the 
filter, washed with water, and dried in vacuum. The desired product 53 was obtained as a 
white powder (0.250 g, 0.431 mmol, yield 81.7%). 
Rf = 0.81 (CHCl3/MeOH = 3/2) 
1H-NMR (in d6-DMSO, 300 MHz) δ 10.7 (s, 1H), 8.16 (t, 1H), 7.96 (d, 1H), 7.73 (d, 1H), 
7.40 (m, 5H), 7.36 (m, 5H), 6.99 (d, 1H), 5.19 (s, 2H), 5.04 (s, 2H), 4.41 (s, 2H), 4.00 (q, 
1H), 3.63 (s, 3H), 3.05 (q, 2H), 1.62 (m, 2H), 1.36 (m, 4H). 
 
Methyl αN-(benzyloxycarbonyl)-εN-[(guanine-9-yl)acetyl]lysinate  
(Cbz-Lys(Gb)-OMe)  (54) 
 To a stirred suspension of 50 (0.101 g, 0.483 mmol) in DMF (3.0 ml) was added 
Cbz-Lys-OMe HCl (0.143 g, 0.432 mmol). After cooling to 0 °C, to this suspension was 
added a solution of PyBrOP (0.286 g, 0.612 mmol) in DMF (1.0 ml) and DIEA (0.270 ml, 
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1.53 mmol) in small portion. After stirring for 2 h in an ice bath, the reaction mixture was 
stirred for another 22 h in room temperature. The reaction mixture was poured into cold 
water (60 ml) and stored in a refrigerator overnight. The precipitate was collected on the 
filter, washed with water, and dried in vacuum. The desired product 54 was obtained as a 
white powder (0.105 g, 0.216 mmol, yield 50.0%). 
Rf = 0.75 (CHCl3/MeOH = 3/2) 
1H NMR (in d6-DMSO, 300 MHz) δ 10.6 (br s, 1H), 8.22 (t, 1H), 8.04 (s, 1H), 7.74 (d, 1H), 
7.37-7.31 (m, 5H), 6.90 (br s, 2H), 5.03 (s, 2H), 4.72 (s, 2H), 3.99 (m, 1H), 3.63 (s, 3H), 
3.05 (q, 2H), 1.64 (m, 2H), 1.36 (m, 4H). 
 
Methyl αN-(benzyloxycarbonyl)-εN-[(thymine-1-yl) acetyl]lysinate 
(Cbz-Lys(Tb)-OMe)  (55) 
 To a stirred suspension of 51 (0.116 g, 0.631 mmol) in DMF (3.0 ml) was added 
Cbz-Lys-OMe HCl (0.140 g, 0.422 mmol). After cooling to 0 °C, to this suspension was 
added a solution of PyBrOP (0.225 g, 0.505 mmol) in DMF (1.0 ml) and DIEA (0.290 ml, 
1.69 mmol) in small portion. After stirring for 2 h in an ice bath, the reaction mixture was 
stirred for another 22 h in room temperature. The reaction mixture was poured into cold 
water (50 ml) and stored in a refrigerator overnight. The precipitate was collected on the 
filter, washed with water, and dried in vacuum. The desired product 55 was obtained as a 
white powder (0.127 g, 0.276 mmol, yield 65.2%). 
Rf = 0.71 (CHCl3/MeOH = 3/2) 
1H-NMR (in d6-DMSO, 300 MHz) δ 11.3 (s, 1H), 8.10 (t, 1H), 7.73 (d, 1H), 7.41 (s, 1H), 
7.34 (m, 5H), 5.03 (s, 2H), 4.24 (s, 2H), 4.00 (q, 1H), 3.63 (s, 3H), 3.03 (d, 2H), 1.74 (s, 
3H), 1.62 (m, 2H), 1.36 (m, 4H). 
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αN-(benzyloxycarbonyl)-εN-[[6-N-(benzyloxycarbonyl)adenine-9-yl]acetyl]lysine 
(Cbz-Lys(Cbz-Ab)-OH) (56) 
 Compound 52 (0.095 g, 0.157 mmol) was dissolved in MeOH (5.0 ml). And 1M NaOH 
aq. (2.0 ml) was added to this solution and stirred for 0.5 h. This reaction mixture was 
concentrated to 20% of original volume and 0.25M HCl aq. was dropped, and it adjusted 
to pH 3 and stored in a refrigerator overnight. Resultant precipitate was collected by 
centrifugation (8000 r.p.m., 15 min.) and dried in vacuum. The desired product 56 was 
obtained as a white powder (0.0562g, 0.0953 mmol, yield 61.0%). 
Rf = 0.50 (CHCl3/MeOH/NH3(aq) = 2/2/1). 
 
αN-(benzyloxycarbonyl)-εN-[[4-N-(benzyloxycarbonyl)-cytosine-1-yl]acetyl]lysine 
(Cbz-Lys(Cbz-Cb)-OH)  (57) 
 Compound 53 (0.164 g, 0.282 mmol) was dissolved in MeOH (7.0 ml). And 1M NaOH 
aq. (2.0 ml) was added to this solution and stirred for 1.0 h. This reaction mixture was 
concentrated to 20% of original volume and 0.25M HCl aq. was dropped, and it adjusted 
to pH 3 and stored in a refrigerator overnight. Resultant precipitate was collected by 
centrifugation (8000 r.p.m., 15 min.) and dried in vacuum. The desired product 57 was 
obtained as a white powder (0.0715g, 0.126 mmol, yield 44.8%). 
Rf = 0.46 (CHCl3/MeOH/NH3(aq) = 2/2/1). 
 
αN-(benzyloxycarbonyl)-εN-[(guanine-9-yl)acetyl]lysine (Cbz-Lys(Gb)-OH)  (58) 
 Compound 54 (0.0920 g, 0.189 mmol) was dissolved in MeOH(3.0 ml). And 1M NaOH 
aq. (1.5 ml) was added to this solution and stirred for 2.0 h. This reaction mixture was 
concentrated to 20% of original volume and 0.25M HCl aq. was dropped, and it adjusted 
to pH 3 and stored in a refrigerator overnight. Resultant precipitate was collected by 
centrifugation (8000 r.p.m., 15 min.) and dried in vacuum. The desired product 58 was 
obtained as a white powder (0.0729g, 0.155 mmol, yield 82.0%). 
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Rf = 0.30 (CHCl3/MeOH/NH3(aq) = 2/2/1). 
 
αN- (benzyloxycarbonyl)-εN-[(thymine-1-yl)acetyl] lysine (Cbz-Lys(Tb)-OH)  (59) 
 Compound 55 (0.123 g, 0.266 mmol) was dissolved in MeOH (5.0 ml). And 1M NaOH 
aq. (1.8 ml) was added to this solution and stirred for 1.0 h. This reaction mixture was 
concentrated to 20% of original volume and 0.25M HCl aq. was dropped, and it adjusted 
to pH 3 and stored in a refrigerator overnight. Resultant precipitate was collected by 
centrifugation (8000 r.p.m., 15 min.) and dried in vacuum. The desired product 59 was 
obtained as a white powder (0.102 g, 0.229 mmol, yield 85.9%). 
Rf = 0.60 (CHCl3/ MeOH /NH3(aq) = 2/2/1). 
 
6’-N-[αN-(benzyloxycarbonyl)-εN-[[6-N-(benzyloxycarbonyl)adenine-9-yl]acetyl] 
lysinyl]neamine (Cbz-Lys (Cbz-Ab)-neamine)  (60) 
 A solution of 56 (0.0530 g, 0.0899 mmol) in DMF (1.0 ml) was cooled to 0 °C. WSC HCl 
(0.0189 g, 0.0986 mmol) was added to this solution and stirred for 3 h. This solution was 
added to a solution of neamine (0.0610 g, 0.189 mmol) in DMF (0.5 ml) and water (1.0 
ml), and stirred for 2 h at 0 °C and another 18 h at room temperature. The reaction 
mixture was evaporated. The crude product was dissolved in 10% acetic acid aqueous 
solution, purified by reversed-phase HPLC (YMC-Pack Pro C18 RS, Φ10 mm x 250 mm). 
The desired product 60 was obtained as a colorless oil (0.0036 g, 0.00403 mmol, yield 
4.5%). 
Rf = 0.30 (CHCl3/MeOH/ NH3(aq) = 5/3/1), 
1H NMR (in D2O, 300 MHz) δ 8.53 (s, 1H), 8.37 (s, 1H), 7.43-7.13 (m, 10H), 5.53 (d, 1H), 
5.26 (s, 2H), 5.01 (s, 4H), 3.93 (m, 1H), 3.70-3.18 (m, majority), 2.36 (m, 1H), 1.60 (m, 
2H), 1.43 (m, 2H), 1.26 (m, 2H). 
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6’-N-[αN-(benzyloxycarbonyl)-εN-[[4-N-(benzyloxycarbonyl)cytosine-1-yl]acetyl]lys
-inyl]neamine (Cbz-Lys(Cbz -Cb)-Neamine)  (61) 
 A solution of 57 (0.0848 g, 0.150 mmol) in DMF (1.0 ml) was cooled to 0 °C. WSC HCl 
(0.0431 g, 0.0225 mmol) was added to this solution and stirred for 2 h. This solution was 
added to a solution of neamine (0.0965 g, 0.300 mmol) in DMF (0.5 ml) and water (1.0 
ml), and stirred for 2 h at 0 °C and another 22 h at room temperature. The reaction 
mixture was evaporated. The crude product was dissolved in 10% acetic acid aqueous 
solution, purified by reversed-phase HPLC (GL Sciences Inc. Intersil ODS-3, Φ10 mm x 
230 mm). The desired product 61 was obtained as a colorless oil (0.0111 g, 0.0125 
mmol, yield 8.3%). 
Rf = 0.39 (CHCl3/MeOH/NH3(aq) = 2/2/1) 
1H NMR (in D2O, 300 MHz) δ 7.60 (d, 1H), 7.27-7.24 (m, 10H), 6.00 (d, 1H), 5.52 (d-t, 
1H), 4.98 (d, 2H), 4.38 (s, 2H), 3.90 (m, 1H), 3.72-3.04 (m, majority), 2.33 (m, 1H), 
1.75-1.51 (m, 2H), 1.37 (m, 2H), 1.23 (m, 2H), 1.01 (t, 1H). 
 
6’-N-[αN-(benzyloxycarbonyl)-εN-[(guanine-9-yl)acetyl]lysinyl]neamine 
(Cbz-Lys(Gb)-Neamine)  (62) 
 A solution of 58 (0.0652 g, 0.138 mmol) in DMF (1.0 ml) was cooled to 0 °C. WSC HCl 
(0.0319 g, 0.154 mmol) was added to this solution and stirred for 2 h. This solution was 
added to a solution of neamine (0.0833 g, 0.256 mmol) in DMF (0.33 ml) and water (0.66 
ml), and stirred for 2 h at 0 °C and another 19 h at room temperature. The reaction 
mixture was evaporated. The crude product was dissolved in 10% acetic acid aqueous 
solution, purified by reversed-phase HPLC (YMC-Pack Pro C18 RS, Φ10 mm x 250 mm). 
The desired product 62 was obtained as a colorless oil (0.0146 g, 0.0188 mmol, yield 
13.6%). 
Rf = 0.43 (CHCl3/MeOH/ NH3(aq) = 2/2/1) 
1H NMR (in D2O, 300 MHz) δ 8.66 (s, 1H), 7.82 (s, 2H), 7.24-7.17 (m, 5H), 5.58 (d, 1H), 
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4.93 (d, 2H), 3.82-3.16 (m, majority), 2.37 (m, 1H), 1.60 (m, 2H), 1.45 (m, 2H), 1.30 (m, 
2H). 
 
6’-N-[αN-(benzyloxycarbonyl)]-εN-](thymine-1-yl)acetyl]lysinyl]neamine 
(Cbz-Lys(Tb)-Neamine)  (63) 
 A solution of 59 (0.109 g, 0.245 mmol) in DMF (1.4 ml) was cooled to 0 °C. WSC HCl 
(0.0583 g, 0.304 mmol) was added to this solution and stirred for 2 h. This solution was 
added to a solution of neamine (0.127 g, 0.393 mmol) in DMF (0.7 ml) and water (1.4 ml), 
and stirred for 2 h at 0 °C and another 22 h at room temperature. The reaction mixture 
was evaporated. The crude product was dissolved in 10% acetic acid aqueous solution, 
purified by reversed-phase HPLC (GL Sciences Inc. Intersil ODS-3, Φ10 mm x 230 mm). 
The desired product 63 was obtained as a colorless oil (0.0461 g, 0.0614 mmol, yield 
25.0%). 
Rf = 0.38 (CHCl3/MeOH/NH3(aq) = 2/2/1) 
1H NMR (in D2O, 300 MHz) δ 7.26-7.21 (m, 6H), 5.52 (d, 1H), 4.98 (d, 2H), 4.25 (s, 2H), 
3.92-3.64 (m, 3H), 3.52-3.07 (m, 8H), 2.33 (m, 1H), 1.69 (s, 3H), 1.57 (m, 2H), 1.36 (m, 
2H), 1.20 (m, 2H). 
 
6’-N-[[εN-(adenine-9-yl)acetyl]lysinyl]neamine (Ab-(D,L)Kε-Neamine)  (64) 
 A solution of 60 (0.0036 g, 0.00403 mmol) in TFA (0.5 ml) were added m-cresol (0.067 
ml, 0.64 mmol), thioanisole (0.113 ml, 0.966 mmol), and trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 0.187 ml, 0.969 mmol) and stirred for 0.5 h at 0 °C, 
2 h at room temperature. The reaction mixture was concentrated to around 0.3 ml, and 
cold Et2O (6.0 ml) was added to this solution. The resultant precipitate was collected by 
centrifugation (6000 r.p.m., 10 min.) and dried in vacuum. The crude product was 
obtained as a white powder and purified by reversed-phase HPLC (YMC-Pack Pro C18 
RS Φ10 mm x 250 mm). The desired product 64 was obtained as a white powder (0.0007 
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g, 0.00117 mmol, 29.0%). 
Rf = 0.025 (CHCl3/MeOH/NH3(aq) = 5/3/1) 
UV (H2O) λmax (ε) 260 (2996) nm 
1H NMR (in D2O, 400 MHz) δ 8.19-8.09 (m, 8H), 5.47 (d, 2H), 5.03-5.01 (m, 8H), 4.85 
(dd 1H), 4.68-4.64 (m, majority), 4.15-4.11 (m, 3H), 3.95 (dd, 2H), 3.73-2.98 (m, majority), 
2.86-2.81 (m, 8H), 2.34-2.22 (m, 3H), 1/70-1.49 (m, majority), 1.38-1.24 (m, 8H) 
13C NMR (in D2O, 100 MHz) δ 174.8, 174.7, 169.4, 169.0, 163.8, 163.4, 149.9, 149.6, 
148.6, 148.5, 144.9, 144.8, 118.6, 118.6, 118.3, 115.4, 97.3, 97.1, 79.4, 79.1, 75.5, 75.4, 
75.3, 75.2, 73.0, 72.3, 71.7, 70.7, 69.1, 69.0, 55.9, 54.9, 54.3, 54.2, 50.2, 49.1, 48.8, 
48.7, 46.3, 40.6, 39.7, 39.7, 31.0, 30.7, 28.8, 28.7, 26.9, 26.8, 22.8, 22.7 
MALDI-TOF MS found M+H+, M+Na+, M+K+ (calcd M+H+, M+Na+, M+K+) 626.0139, 
647.9873, 663.9427 (626.3369, 648.3188, 664.2928) 
 
6’-N-[[εN-(cytosine-1-yl)acetyl]lysinyl]neamine (Cb-(D,L)Kε-Neamine)  (65) 
 A solution of 61 (0.0111 g, 0.0125 mmol) in TFA (0.5 ml) were added m-cresol (0.080 
ml, 0.764 mmol), thioanisole (0.088 ml, 0.753 mmol), and trimethylsilyl trifluoromethane- 
sulfonate (TMSOTf, 0.145 ml, 0.750 mmol) and stirred for 0.5 h at 0 °C, 3 h at room 
temperature. The reaction mixture was concentrated to around 0.3 ml, and cold Et2O (5.0 
ml) was added to this solution. The resultant precipitate was collected by centrifugation 
(6000 r.p.m., 10 min.) and dried in vacuum. The crude product was obtained as a white 
powder and purified by reversed-phase HPLC (GL Sciences Inc. Intersil ODS-3, Φ10 mm 
x 230 mm). The desired product 65 was obtained as a white powder (0.0059 g, 0.00972 
mmol, 77.6%). 
Rf = 0.13 (CHCl3/MeOH/NH3 (aq) = 2/2/1) 
UV (H2O) λmax (ε) 272 (1477) nm 
1H NMR (in D2O, 400 MHz) δ 7.43-7.39 (m, 3H), 5.89-5.86 (m, 3H), 5.54 (d, 1H), 5.35 (d, 
1H), 4.79-4.60 (m, majority), 4.53-4.51 (m, 7H), 4.43-4.30 (m, 4H), 4.12-4.08 (m, 2H), 
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3.98 (m, 1H), 3.73-3.12 (m, majority), 2.83-2.79 (m, 7H), 2.30-2.26 (m, 2H), 1.73-1.47 (m, 
majority), 1.38-1.16 (m, 8H) 
13C NMR (in D2O, 100 MHz) δ 170.5, 170.4, 163.8, 163.4, 148.3, 148.1, 118.3, 115.4, 
97.5, 97.0, 96.5, 96.3, 79.6, 79.2, 75.5, 75.4, 73.0, 72.5, 71.4, 71.4, 71.3, 71.2, 70.6, 
70.5, 69.2, 69.1, 55.3, 54.8, 54.3, 54.2, 52.7, 52.6, 50.2, 50.1, 49.2, 48.9, 39.7, 39.6, 
30.8, 30.6, 28.8, 28.7, 26.8, 26.7, 26.7. 26.6, 22.7, 22.6 
MALDI-TOF MS found M+H+, M+Na+, M+K+ (calcd M+H+, M+Na+, M+K+) 602.5131, 
624.4747, 640.4361 (602.3257, 624.3076, 640.2815) 
 
6’-N-[[εN-(guanine-9-yl)acetyl]lysinyl]neamine (Gb-(D,L)Kε-Neamine)  (66) 
 A solution of 62 (0.0146 g, 0.0188 mmol) in TFA (0.5 ml) were added m-cresol (0.0601 
ml, 0.573 mmol), thioanisole (0.067 ml, 0.573 mmol), and trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 0.110 ml, 0.570 mmol) and stirred for 0.5 h at 0 °C, 
2.5 h at room tempera- ture. The reaction mixture was concentrated to around 0.3 ml, 
and cold Et2O (10.0 ml) was added to this solution. The resultant precipitate was 
collected by centrifugation (6000 rpm, 10 min.) and dried in vacuum. The crude product 
was obtained as a white powder and purified by reversed-phase HPLC (YMC-Pack Pro 
C18 RS Φ10 mm x 250 mm). The desired product 66 was obtained as a white powder 
(0.0075 g, 0.0120 mmol, 63.8%). 
Rf = 0.038 (CHCl3/MeOH/NH3 (aq) = 2/2/1) 
UV (H2O) λmax (ε) 252 (2886) nm, λmax (ε) 270 (2094) nm. 
1H NMR (in D2O, 400 MHz) δ 7.63-7.54 (m, 6H), 5.26 (d, 1H), 4.71-4.49 (m, majority), 
3.96-3.92 (m, 2H), 3.75 (m, 1H), 3.59-2.82 (m, majority), 2.75-2.70 (m, majority), 
2.10-2.05 (m, 4H), 1.62-1.12 (m, majority) 
13C NMR (in D2O, 100 MHz) δ 174.7, 174.4, 169.9, 169.5, 159.6, 159.5, 154.7, 154.6, 
152.6, 152.5, 141.0, 140.9, 121.7, 118.6, 116.2, 115.4, 97.5, 97.0, 75.5, 75.3, 73.0, 72.9, 
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72.6, 72.5, 71.9, 70.9, 70.2, 69.7, 69.1, 69.0, 56.3, 55.1, 54.4, 54.3, 54.2, 50.1, 49.2, 
48.7, 46.3, 46.0, 41.4, 40.1, 39.7, 39.6, 30.5, 30.4, 28.9, 28.8, 26.9, 26.8, 22.9, 22.8. 
MALDI-TOF MS found M+H+, M+Na+, M+K+ (calcd M+H+, M+ Na+, M+K+) 641.7694, 
663.7467, 679.7185 (642.3318, 664.3137, 680.2877).  
 
6’-N-[[εN-(thymine-1-yl)acetyl]lysinyl]neamine (Tb-(L)Kε-Neamine)  (67) 
 A solution of 63 (0.0461 g, 0.0614 mmol) in TFA (1.0 ml) were added m-cresol (0.0126 
ml, 0.120 mmol), thioanisole (0.211 ml, 1.80 mmol), and trimethylsilyl trifluoromethane- 
sulfonate (TMSOTf, 0.349 ml, 1.80 mmol) and stirred for 0.5 h at 0 °C, 2 h at room 
temperature. The reaction mixture was concentrated to around 0.6 ml, and cold Et2O 
(10.0 ml) was added to this solution. The resultant precipitate was collected by 
centrifugation (6000 r.p.m., 10 min.) and dried in vacuum. The crude product was 
obtained as a white powder and purified by reversed-phase HPLC (GL Sciences Inc. 
Intersil ODS-3, Φ10 mm x 230 mm). The desired product 67 was obtained as a white 
powder (0.0205 g, 0.0332 mmol, 54.1%). 
Rf = 0.29 (CHCl3/MeOH/NH3 (aq) = 2/2/1) 
UV (H2O) λmax (ε) 268 (2579) nm 
1H NMR (in D2O, 400 MHz) δ 7.29-7.22 (m, 5H), 5.44 (d, 3H), 5.28 (d, 1H), 4.72-4.61 (m, 
majority), 4.39-4.29 (m, 9H), 4.13-4.09 (m, 3H), 3.99 (m, 1H), 3.70-3.04 (m, majority), 
2.81-2.78 (m, 9H), 2.22-2.17 (m, 4H), 1.76-1.21 (m, majority) 
13C NMR (in D2O, 100 MHz) δ 174.8, 170.0, 167.6, 163.4, 152.8, 143.7, 118.3, 115.4, 
111.6, 97.3, 75.6, 73.3, 72.3, 70.7, 69.5, 54.6, 54.4, 51.1, 50.4, 49.1, 39.7, 30.9, 26.8, 
22.7, 11.8 
MALDI-TOF MS found M+H+, M+Na+, M+K+ (calcd M+H+, M+Na+, M+K+) 616.6538, 
638.6233, 654.5807 (617.3253, 639.3073, 655.2812).  
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Chapter 5  Binding of nucleobase modified neamine to TAR and RRE RNA 
derived from HIV-1 
5-1.  Introduction 
5-1-1. Target hairpin RNAs (HIV-1 TAR RNA and HIV-1 RRERNA) 
 
 The aim of this study is the discovery of the molecule that eventually inhibits the 
replication of an HIV. One of conventional drug that combat HIV are protease inhibitor. 
However, It was known that HIV acquired resistance for the protease inhibitors. On the 
replication of HIV, two viral proteins (Tat and Rev) are known as activators that bind to 
the activator region of the viral RNA (HIV-1 TAR RNA and HIV-1 RRE RNA), then amplify 
the replication of HIV. On this circumstance, I have decided to discover for the compound 
which binds to HIV-1 TAR RNA or HIV-1 RRE RNA specifically in order to inhibit the 
binding of viral peptide with the RNA (Figure 5-1)1,2. Then I have chosen TAR and RRE 
RNA as the targets and designed trehalosamine and NbKε-neamine as a scaffold. And, I 
evaluate about inhibition of TAR-Tat and RRE-Rev. 
 
 
 
Figure 5-1  HIV-1 TAR RNA(31 nts) and HIV-1RRE RNA(47 nts) 
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5-1-2. The binding study for the evaluation of nucleobase-modified neamines as 
the inhibitor for either TAR-Tat or RRE-Rev. 
 
 In this chapter, I describe the evaluation of the trehalosamine and NbKε-neamine as 
inhibitors of TAR-Tat and RRE-Rev. The evaluation method adopted the spectroscopic 
method using fluorescence peptide as a tracer, and it aimed at clarifying detailed relation 
between the steric structure of the molecule and RNA binding capacity. 
 
The evaluation methods for the binding of neamine derivatives to TAR RNA 
 For the evaluation of the neamine derivatives as the binding inhibitor for TAR RNA, 
fluorescently labeled Tat peptide, FTatRhd3 was employed as the binding tracer (Figure 
5-2). Upon the binding, Tat peptide was bended by TAR RNA, as a result two fluorescent 
dyes were placed closer proximity for FRET emission, then fluorescence emission 
increases with increasing concentration of TAR RNA. On the other hand, FRET emission 
(fluorescence intensity of FtatRhd around 577nm) was decreased with increasing 
concentration of neamine derivatives. Dissociation constants of the neamine derivatives 
(drags) were determined by the curve-fitting analysis with the Eq.(1) of 1:1 stoichiometry 
(Refer to 5-4. Experimental Section).4 
 
 
Figure 5-2  Amino acid sequence of the fluorescent Tat peptide (FTatRhod) 
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The evaluation methods for the binding of neamine derivatives to RRE RNA 
 For the binding study of the neamine derivatives with RRE RNA, fluorescein-labeled 
Rev peptide, FLRev2, was employed as the binding tracer (Figure 5-3). On the binding of 
FLRev with RRE, increasing fluorescence anisotropy of FLRev around 520 nm was 
observed. When the neamine derivatives compete with the probe, the fluorescent 
anisotropy should decrease. On the other hand, when the neamine derivatives bound not 
with FLRev but with RRE-FLRev complex, fluorescence anisotropy was more increased. 
Dissociation constants of the neamine derivatives were determined by the curve-fitting 
analysis with the Eq.(2) of 1:1 stoichiometry (Refer to 5-4. Experimental Section).5 
 
 
 
Figure 5-3  Amino acid sequence of the fluorescent Rev peptide (FLRev) 
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5-2.  Results and Discussion 
5-2-1. Binding of neamine derivatives toward the HIV-1 TAR RNA 
 
 For the evaluation of the trehalosamine as the binding inhibitor for TAR RNA, 
fluorescently labeled Tat peptide, FTatRhd3 was employed as the binding tracer. In the 
complex of TAR-Tat, Tat peptide forms β-turm, as a result, two fluorescent dyes were 
placed closer proximity for FRET emission, therefore fluorescence emission increases 
with increasing concentration of TAR RNA. On the other hand, if αα, αβ and 
ββ-trehalosamine bind to the TAR RNA, FRET emission was decreased. However, 
FRET emission has not changed much with increasing concentration of αα, αβ and 
ββ-trehalosamine (0 - 800 µM) (Figure 5-4). These results denoted that αα, αβ, 
ββ-trehalosamine did not bind to the TAR RNA, although neamine bound the RNA with 
considerable affinity (Figure 5-5). Since the part of the sugar backbone of neamine has 
similar structure as trehalosamine, it was suggested that the unit of deoxystreptamine in 
a neamine is greatly related to affect the binding toward TAR RNA. These results have 
shown that the binding affinity toward the RNA varies greatly depend on the slight 
difference in the structure of the disaccharide and the position of amino groups. 
Therefore, it is thought that the new design of novel small compounds with low molecular 
weight requires more precise examinations. 
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Figure 5-4  Fluorescence titration curves as a function of the concentration of αα, αβ 
                      and ββ-trehalosamine. The concentrations of TAR RNA and FtatRhd were  
           fixed at 800 and 100 nM, respectively. 
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Figure 5-5  Dissociation constants (Kd) of the neamine derivatives for TAR RNA 
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 In the binding experiment of NbKε-neamine with TAR RNA, fluorescently labeled Tat 
peptide, FTatRhd3 was employed as the binding tracer. Upon the binding with TAR, Tat 
peptide forms β-turn, as a result, two fluorescent dyes were placed closer proximity for 
FRET emission, therefore fluorescence emission increases with increasing 
concentration of TAR RNA. On the other hand, FRET emission was decreased with 
increasing concentration of NbKε-neamine (Figure 5-6, 5-7 Spectra and plots).6 The data 
points of each binding experiment were fitted finely with the theoretical curve with 1:1 
stoichiometry. Then dissociation constants between NbKε-neamines and TAR RNA were 
determined and summarized in Table 5-1. The dissociation constant of neamine with 
TAR RNA was 28 µM. That of Ab, Cb, Gb and Tb-Kε-neamine were 0.74, 1.4, 0.24 and 
0.86 µM, respectively. The modification of the neamine with the nucleobase enhanced 
binding affinity 20 to 100 times smaller than native neamine. Among four 
NbKε-neamines, Gb-Kε-neamine has shown the highest affinity for the binding to TAR 
RNA. The adenine and the guanine in the NbKε-neamines have potential to interact with 
the uracil and cytosine in the tri bulge of TAR RNA. Even though the buldge does not 
have any adenine, the binding of Tb-Kε-neamine was comparable to that of 
Ab-Kε-neamine. Despite Watson-Crick type base pairing of A22-U40 would be predicted 
from the secondary structure of TAR RNA for A22-U40 of which locating at the lower 
stem of the tri bulge, hydrogen bonds of this base pairings are relaxed due to twist 
across the tri base bulge, C24 stack on U23 and U23 stack on A22.2,5,7 This structural 
feature of TAR RNA may make the thymine of Tb-Kε-neamine interact with the A22. Only 
the cytosine of Cb-Kε-neamine has no possible to interact with the bases around the 
bulge. That is the reason why CbKe-neamine does not bind as the other three(Figure 
5-8). 
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Figure 5-6  Fluorescence spectra of FtatRhd in the absence and in the presence of  
           various concentrations of Ab, CbKε-Neamine (left) and fluorescence titration  
           curves as a function of the concentration of Ab,CbKε-Neamine(right).  
           The concentrations of TAR RNA and FtatRhd were fixed at 800 and 100 nM 
           respectively. 
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Figure 5-7  Fluorescence spectra of FtatRhd in the absence and in the presence of  
           various concentrations of Gb, TbKε-Neamine (left) and fluorescence titration  
           curves as a function of the concentration of Gb,TbKε-Neamine(right).  
           The concentrations of TAR RNA and FtatRhd were fixed at 800 and 100 nM 
           respectively. 
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Table 5-1  Dissociation constants(Kd) of the neamine derivatives for TAR RNA 
 
Compounds Kd (μM) 
Neamine   28 a 
K-Neamine   19 a 
AbKε-Neamine    0.74 
CbKε-Neamine    1.4 
GbKε-Neamine    0.24 
TbKε-Neamine    0.86 
                               a Ref. 1 
 
 
 
 
Figure 5-8  Possible explanation for the difference of the binding affinity of  
           NbKε-neamine with TAR RNA. 
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5-2-2. Binding of neamine derivatives toward the HIV-1 RRE RNA 
 
 For the binding study of NbKε-neamines with RRE RNA, fluorescein labeled Rev 
peptide, FLRev2, was used as the probe. On the binding of FLRev with RRE, increasing 
fluorescence anisotropy was observed. When the compound competes with the probe, 
the fluorescent anisotropy should decrease. However, neamine and l-lysine modified 
neamine (K-neamine) and all four NbKε-neamines keep increased fluorescence 
anisotropy of RRE-FLRev complex with the increasing concentration of neamine and its 
derivatives (Figure 5-9). On the other hand, in the absence of RRE, neamine and its 
derivatives did not increase the fluorescent anisotropy of FLRev. These results indicate 
that NbKε-neamine bound not with FLRev but with RRE-FLRev complex. Multiple 
binding site of RRE was suggested for neomycin B.8 The primary binding site for 
neomycin B is independent from the that for Rev. Similar to neomycin B. Due to tight 
binding of RRE-FLRev complex, neamine and its derivatives do not compete with FLRev, 
they might bind the independent binding site from that of FLRev (Figure 5-10). The 
binding magnitude of the neamine derivative were determined as the dissociation 
constants from the increasing fluorescence anisotropy of FLRev-RRE and summarized 
in Table 5-2. Although the modification of neamine with lysine did not enhance its binding 
(neamine; 5.4 µM, K-neamine; Kd = 5.7 µM), NbKε-neamine obviously enhanced its 
binding toward RRE-FLRev (NbKε-neamine; 0.53-0.64 µM). However, NbKε-neamines 
were not effective as the binding inhibitor for RRE-Rev. 
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Figure 5-9  Fluorescence titration curve as a function of the increasing concentration  
           of Neamine, K-Neamine, NbKε-Neamine. The concentrations of both RRE  
           RNA and FLRev were fixed at 10 nM. 
 
 
１１１ 
 
Figure 5-10  The presumed binding site of neamine derivatives 
 
 
Table 5-2. Dissociation constants of the neamine derivatives for RRE RNA 
 
Compounds Kd (μM) 
Neamine     5.6  
K-Neamine     6.9 
AbKε-Neamine     0.57 
CbKε-Neamine     0.64 
GbKε-Neamine     0.53 
TbKε-Neamine     0.57 
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5-3.  Conclusion 
 
 In this chapter, I described the evaluation of the trehalosamine and NbKε-neamine as 
inhibitors of TAR-Tat and RRE-Rev. The spectroscopic method using fluorescent peptide 
as a tracer, and it aimed at clarifying detailed binding behavior of neamine derivatives 
with the RNAs. 
 In chapter 5−2−1, I described the evaluation of the trehalosamine and NbKε-neamine 
as inhibitors of TAR-Tat. Despite neamine bind to TAR RNA with the dissociation 
constant (Kd) of 28 µM, αα, αβ, ββ-trehalosamine did not bind to the TAR RNA, even if 
treharosamin is structurally resemble to neamine. It is considered that the unit of 
deoxystreptamine of in neamine is greatly related to the binding with TAR RNA. This 
study made it clear that the slight difference in the structure of the disaccharide and the 
position of the amino group strongly affect the binding affinities with the specific RNA 
fragment. NbKε-neamine bound TAR RNA competing with Tat. Among four of 
NbKε-neamines, GbKε-neamine denotes the highest binding with TAR, AbKε-neamine 
and TbKε-neamine follow that of GbKε-neamine. These three bases are able to interact 
with the nucleobases around the tri base of bulge in TAR RNA.  
 In chapter 5−2−2, I described the evaluation of the NbKε-neamine as inhibitors of 
RRE-Rev. NbKε-neamines bind to RRE with relatively high affinity, however due to 
independent binding site of RRE for aminoglycosides other than for Rev peptide, 
NbKε-neamines could not be an inhibitor for Rev, one of the activator of HIV-1. All the 
NbKε-neamines enhanced its binding affinities for RRE about 10 times higher than that 
of neamine itself. But that was not depends on the difference of nucleobase of the 
compound except for GbKε-neamine having slightly better affinity than the others. An 
appropriate modification with the nucleobase on the neamine enhanced it binding affinity 
for the RNA. NbKε-neamines act as competitive inhibitor for TAR-Tat but not for 
RRE-Rev, and that inhibitory capacity was depend on the nucleobase of NbKε-neamine. 
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5-4.  Experimental Section 
 
 Steady state fluorescence spectroscopy was performed at 25oC on a HITACHI F3000 
or F2500 fluorescence spectrophotometer. 
 
Evaluation as binding inhibitor for TAR-Tat 
 Fluorescent Tat peptide, FtatRhd3, was employed as a tracer to monitor the inhibition 
for TAR-Tat.4 On the addition of the drugs, fluorescence intensity of FtatRhd around 
577nm was decreased. Dissociation constants of the neamine derivatives were 
determined by the curve-fitting analysis with the Eq.(1) of 1:1 stoichiometry. 
 
[neamine derivatives]0 = ( KD ( i∞ − i ) / Kd ( i − i0) + 1 ) × ( [TAR-FtatRhd]0 − Kd ( i − i0) / 
( i∞ − i ) − [FtatRhd]0 ( i − i0) / ( i∞ − i0 ) )                                      (1) 
 
 The parameters, i and i0 of Eq.(1) are fluorescence intensities of FtatRhd in the 
presence and absence of the TAR-RNA, respectively, and i∞ is the fluorescence intensity 
in the presence of infinite concentration of the neamine derivatives. [neamine 
derivatives]0 is the initial concentration of the neamine derivatives, KD and Kd are the 
dissociation constants of TAR, neamine derivatives and TAR-FtatRhd complex, 
respectively. The concentrations of [FtatRhd]0 and [TAR-FtatRhd]0 were fixed at 100 and 
800 nM, respectively. The concentrations [neamine derivatives] were varied from 0 to 40 
µM. Fluorescence intensity of FtatRhd was measured at 580 nm for each concentration 
of neamine derivatives. 
 
Evaluation as binding inhibitor for RRE-Rev 
 Fluorescent Rev peptide, FLRev2, was employed as a tracer to monitor the inhibition for 
RRE-Rev.5 On the addition of the neamine derivatives, fluorescence anisotropy of FLRev 
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around 520 nm was more increased. Dissociation constants of the neamine derivatives 
were determined by the curve-fitting analysis with the Eq.(2) of 1:1 stoichiometry. 
 
i = io + Δi ( [FLRev]0 + [neamine derivatives]0 + Kd – (([FLRev]0 + [neamine derivatives]0 
+ Kd)2 – 4 [FLRev]0 × [neamine derivatives]0 )0.5 ) / 2                              (2) 
 
 The parameters, i and i0 of Eq. (2)  are fluorescence anisotropies of FLRev in the 
presence and absence of the RRE-RNA, respectively, and Δi is the amount of 
fluorescence anisotropy change by unit concentration change of the neamine derivatives. 
[neamine derivatives]0 is the initial concentration of the neamine derivatives, Kd is the 
dissociation constants of RRE-Neamine complex. The concentrations, [FLRev]0 and 
[RRE] were fixed at 10 nM. The concentrations of neamine derivatives were varied from 
0 to 5 µM. Fluorescence anisotropy of FLRev was measured at 520 nm for each 
concentration of neamine derivatives. 
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Chapter 6  Summary 
 
 Although design of sequence-specific DNA-binding molecules have been established, 
due to its intricate structure, that for RNA has not been established yet. However, a few 
examples for the design of the RNA-binding molecules have been reported. One strategy 
is based on the polycyclic stacking molecule as a starting material, such as ethidium or 
acridine, the other is employing RNA-binding natural compounds as the scaffold, such as 
aminoglycoside antibiotics. There are two major aims to construct an RNA-binding 
molecule starting from the aminoglycoside. One aim is how to enhance the binding 
affinities of the aminoglycoside toward RNA. The other is how to acquire the binding 
specificity. Due to positive charge of the aminoglycoside antibiotics, the driving force of 
the binding interaction depends on electrostatic interaction. That kind of interaction may 
abolish binding specificity. 
 On the other hand, it has been known that replication of the human immunodeficiency 
virus (HIV) genome is regulated by virally encoded regulatory proteins, trans-activator 
protein (Tat) and retroviral protein (Rev), those two proteins bind to the specific region of 
the viral hairpin RNAs, trance-activator responsive region (TAR) and Rev responsive 
element (RRE), respectively. The molecule that compete with Tat and Rev protein may 
act as an inhibitor for above two regulations. 
 
 In this study, I have been trying to discover the novel compound specifically binds to 
HIV-1 RNA in order to inhibit the multiplication of an HIV, eventualy. As described in 1-3 
and 1-4, a number of groups attempted neamine as a minimum skeleton that bind RNA 
and employed as a scaffold to construct an RNA binding reagent. However, most of the 
small molecules reported so far have indicated only a modest affinity and selectivity for 
RNA. Then I have chosen TAR and RRE RNA as the targets and designed 
trehalosamine, aromatic aminoglycoside and NbKε-neamine. And, I evaluate those 
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neamine mimics and derivatives about inhibition of TAR-Tat and RRE-Rev. 
 
 In chapter 2, I focused on structure of non-reducing disaccharides that is one of the 
novel neamine analogs, and describe the development of the useful glycosylation 
method to construction of non-reducing disaccharide. In chapter 2-2-1, we developed the 
condensation method of 1-hydroxy sugars with several alcohols in the presence of 
Bi(OTf)3. The reactions of several benzylated 1-hydroxy sugars with certain primary 
alcohols using only 5 mol% Bi(OTf)3 at reflux temperature in dichloromethane for 15 min 
successfully afforded the desired O-glycosides in good yields. In chapter 2-2-2, we 
described the synthesis of the various non-reducing disaccharides composition by the 
efficient dehydrative glycosylation reaction which used Bi(OTf)3. In chapter 2-2-2-1, we 
examined the optimal conditions for carrying out the self-condensation of these, using 
glucose, mannose, galactose, 2-N3-glucose, 2-N3-6-OAc-glucose and arabinose as 
1-hydroxy sugars. Self-condensation with 1-hydroxy sugars was promoted by 10-100 
mol% Bi(OTf)3 at room temperature in dichloromethane for 1d and produced various 
1,1’-disaccharides. In chapter 2-2-2-2, I described the stereospecificity of non-reducing 
disaccharide formation. Therefore, I have established the novel dehydrative 
glycosydation which can build a 1,1’-disaccharide structure efficiently. 
 In chapter 3, I described the synthetic approach to trehalosamine and aromatic 
aminoglycoside as the neamine mimics. In chapter 3−2−1, I described about the 
synthesis of novel non-reducing amino disaccharides (trehalosamine). I succeeded the 
synthesis of trehalosamine as three structural isomers (αα, αβ, ββ) which the 
2,6-position is NH2 in good yield. In chapter 3−2−2, I described about the synthesis of 
aromatic modified amino saccharide (aromatic aminoglycoside). The precursor of the 
aromatic aminoglycoside was synthesized from N-acetyl-D-glucosamine and 
1,3-diaminophenol based on the glycosylation technique. However, the final removal of 
the protection groups was failed.  
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 In chapter 4, I described the synthetic approach to nucleobase modified neamines. 
Lysine was employed as a linker which connect a nucleobse and a neamine. The nucleo 
base was connected at the ε-amino group of a lysine as that a placing the nucleobase 
with an appropriate distance from the scaffold of neamine (NbKε-namines). The four 
novel nucleobase modified neamine with L-lysine as the linker (NbKε-neamine) were 
successfully obtained as the novel small compound expected to bind TAR or RRE RNA 
specifically. 
 In chapter 5, I described the evaluation of the trehalosamine and NbKε-neamine as 
inhibitors of TAR-Tat and RRE-Rev. In chapter 5−2−1, I described the evaluation of the 
trehalosamine and NbKε-neamine as inhibitors of TAR-Tat. It was not observed the 
binding of αα, αβ, ββ-trehalosamine did not bind with the TAR RNA, although neamine 
had bind to the RNA. It became clear that the RNA-binding affinities vary greatly 
according to the slight difference in the structure and the position of amino groups. 
NbKε-neamine bound to TAR RNA as a competitor for Tat. Among four of 
NbKε-neamines, GbKε-neamine denotes the highest binding to TAR, AbKε-neamine and 
TbKε-neamine followed that of GbKε-neamine. These three bases are potentially able to 
interact with the nucleobases around the tri base of bulge in TAR RNA. In chapter 5−2−2, 
I described the evaluation of the “NbKε-neamine” as inhibitors of RRE-Rev. 
NbKε-neamines bind RRE with relatively high affinity. However the binding site for 
NbKε-neamine is independent from that of Rev. As a result, NbKε-neamine is not able to 
competitive with Rev. All the NbKε-neamines enhanced its binding affinities for RRE 
about 10 times higher than that of neamine itself. But there is no difference that depend 
on the nucleobase. An appropriate modification with the nucleobase on the neamine 
enhanced it binding affinity for the RNA. NbKε-neamines act as competitive inhibitor for 
TAR-Tat but not for RRE-Rev, and that inhibition magnitude was depend on the 
nucleobase of NbKε-neamine. 
 NbKε-neamine could be a candidate of potential inhibitor for TAR-Tat. It is expected 
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that the results obtained in this study will be useful for the discovery of the compound 
specifically bind to HIV-1 RNA in order to inhibit the multiplication mechanism of a HIV. 
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